context stringlengths 21 33.9k | category stringclasses 2
values | entity stringlengths 1 12 | entity_type stringclasses 5
values | query stringlengths 97 3.31k | answer stringlengths 12 169 |
|---|---|---|---|---|---|
Includes $ 390 million due to ComEd and PECO financing trusts. | text | 390 | monetaryItemType | text: <entity> 390 </entity> <entity type> monetaryItemType </entity type> <context> Includes $ 390 million due to ComEd and PECO financing trusts. </context> | us-gaap:LongTermDebt |
Includes $ 206 million due to ComEd financing trust. | text | 206 | monetaryItemType | text: <entity> 206 </entity> <entity type> monetaryItemType </entity type> <context> Includes $ 206 million due to ComEd financing trust. </context> | us-gaap:LongTermDebt |
Includes $ 184 million due to PECO financing trusts. | text | 184 | monetaryItemType | text: <entity> 184 </entity> <entity type> monetaryItemType </entity type> <context> Includes $ 184 million due to PECO financing trusts. </context> | us-gaap:LongTermDebt |
During the twelve months ended December 31, 2024, Exelon repurchased a portion of its Senior unsecured notes with a principal balance of $ 244 million outstanding in exchange for cash of $ 215 million. The repurchase was accounted for as a debt extinguishment and resulted in a pre-tax gain of $ 28 million, which is reflected on Exelon's Consolidated Statement of Operations and Comprehensive income within Interest expense, net. | text | 244 | monetaryItemType | text: <entity> 244 </entity> <entity type> monetaryItemType </entity type> <context> During the twelve months ended December 31, 2024, Exelon repurchased a portion of its Senior unsecured notes with a principal balance of $ 244 million outstanding in exchange for cash of $ 215 million. The repurchase was accounted for as a debt extinguishment and resulted in a pre-tax gain of $ 28 million, which is reflected on Exelon's Consolidated Statement of Operations and Comprehensive income within Interest expense, net. </context> | us-gaap:DebtInstrumentRepurchasedFaceAmount |
During the twelve months ended December 31, 2024, Exelon repurchased a portion of its Senior unsecured notes with a principal balance of $ 244 million outstanding in exchange for cash of $ 215 million. The repurchase was accounted for as a debt extinguishment and resulted in a pre-tax gain of $ 28 million, which is reflected on Exelon's Consolidated Statement of Operations and Comprehensive income within Interest expense, net. | text | 215 | monetaryItemType | text: <entity> 215 </entity> <entity type> monetaryItemType </entity type> <context> During the twelve months ended December 31, 2024, Exelon repurchased a portion of its Senior unsecured notes with a principal balance of $ 244 million outstanding in exchange for cash of $ 215 million. The repurchase was accounted for as a debt extinguishment and resulted in a pre-tax gain of $ 28 million, which is reflected on Exelon's Consolidated Statement of Operations and Comprehensive income within Interest expense, net. </context> | us-gaap:RepaymentsOfLongTermDebt |
During the twelve months ended December 31, 2024, Exelon repurchased a portion of its Senior unsecured notes with a principal balance of $ 244 million outstanding in exchange for cash of $ 215 million. The repurchase was accounted for as a debt extinguishment and resulted in a pre-tax gain of $ 28 million, which is reflected on Exelon's Consolidated Statement of Operations and Comprehensive income within Interest expense, net. | text | 28 | monetaryItemType | text: <entity> 28 </entity> <entity type> monetaryItemType </entity type> <context> During the twelve months ended December 31, 2024, Exelon repurchased a portion of its Senior unsecured notes with a principal balance of $ 244 million outstanding in exchange for cash of $ 215 million. The repurchase was accounted for as a debt extinguishment and resulted in a pre-tax gain of $ 28 million, which is reflected on Exelon's Consolidated Statement of Operations and Comprehensive income within Interest expense, net. </context> | us-gaap:GainsLossesOnExtinguishmentOfDebt |
Excludes cash of $ 219 million and $ 334 million at December 31, 2024 and 2023, respectively, and restricted cash of $ 176 million and $ 149 million at December 31, 2024 and 2023, respectively, and includes long-term restricted cash of $ 41 million and $ 174 million at December 31, 2024 and 2023, respectively, which is reported in Other deferred debits in the Consolidated Balance Sheets. | text | 219 | monetaryItemType | text: <entity> 219 </entity> <entity type> monetaryItemType </entity type> <context> Excludes cash of $ 219 million and $ 334 million at December 31, 2024 and 2023, respectively, and restricted cash of $ 176 million and $ 149 million at December 31, 2024 and 2023, respectively, and includes long-term restricted cash of $ 41 million and $ 174 million at December 31, 2024 and 2023, respectively, which is reported in Other deferred debits in the Consolidated Balance Sheets. </context> | us-gaap:CashAndCashEquivalentsFairValueDisclosure |
Excludes cash of $ 219 million and $ 334 million at December 31, 2024 and 2023, respectively, and restricted cash of $ 176 million and $ 149 million at December 31, 2024 and 2023, respectively, and includes long-term restricted cash of $ 41 million and $ 174 million at December 31, 2024 and 2023, respectively, which is reported in Other deferred debits in the Consolidated Balance Sheets. | text | 334 | monetaryItemType | text: <entity> 334 </entity> <entity type> monetaryItemType </entity type> <context> Excludes cash of $ 219 million and $ 334 million at December 31, 2024 and 2023, respectively, and restricted cash of $ 176 million and $ 149 million at December 31, 2024 and 2023, respectively, and includes long-term restricted cash of $ 41 million and $ 174 million at December 31, 2024 and 2023, respectively, which is reported in Other deferred debits in the Consolidated Balance Sheets. </context> | us-gaap:CashAndCashEquivalentsFairValueDisclosure |
Excludes cash of $ 219 million and $ 334 million at December 31, 2024 and 2023, respectively, and restricted cash of $ 176 million and $ 149 million at December 31, 2024 and 2023, respectively, and includes long-term restricted cash of $ 41 million and $ 174 million at December 31, 2024 and 2023, respectively, which is reported in Other deferred debits in the Consolidated Balance Sheets. | text | 176 | monetaryItemType | text: <entity> 176 </entity> <entity type> monetaryItemType </entity type> <context> Excludes cash of $ 219 million and $ 334 million at December 31, 2024 and 2023, respectively, and restricted cash of $ 176 million and $ 149 million at December 31, 2024 and 2023, respectively, and includes long-term restricted cash of $ 41 million and $ 174 million at December 31, 2024 and 2023, respectively, which is reported in Other deferred debits in the Consolidated Balance Sheets. </context> | us-gaap:CashAndCashEquivalentsFairValueDisclosure |
Excludes cash of $ 219 million and $ 334 million at December 31, 2024 and 2023, respectively, and restricted cash of $ 176 million and $ 149 million at December 31, 2024 and 2023, respectively, and includes long-term restricted cash of $ 41 million and $ 174 million at December 31, 2024 and 2023, respectively, which is reported in Other deferred debits in the Consolidated Balance Sheets. | text | 149 | monetaryItemType | text: <entity> 149 </entity> <entity type> monetaryItemType </entity type> <context> Excludes cash of $ 219 million and $ 334 million at December 31, 2024 and 2023, respectively, and restricted cash of $ 176 million and $ 149 million at December 31, 2024 and 2023, respectively, and includes long-term restricted cash of $ 41 million and $ 174 million at December 31, 2024 and 2023, respectively, which is reported in Other deferred debits in the Consolidated Balance Sheets. </context> | us-gaap:CashAndCashEquivalentsFairValueDisclosure |
Excludes cash of $ 219 million and $ 334 million at December 31, 2024 and 2023, respectively, and restricted cash of $ 176 million and $ 149 million at December 31, 2024 and 2023, respectively, and includes long-term restricted cash of $ 41 million and $ 174 million at December 31, 2024 and 2023, respectively, which is reported in Other deferred debits in the Consolidated Balance Sheets. | text | 41 | monetaryItemType | text: <entity> 41 </entity> <entity type> monetaryItemType </entity type> <context> Excludes cash of $ 219 million and $ 334 million at December 31, 2024 and 2023, respectively, and restricted cash of $ 176 million and $ 149 million at December 31, 2024 and 2023, respectively, and includes long-term restricted cash of $ 41 million and $ 174 million at December 31, 2024 and 2023, respectively, which is reported in Other deferred debits in the Consolidated Balance Sheets. </context> | us-gaap:CashAndCashEquivalentsFairValueDisclosure |
Excludes cash of $ 219 million and $ 334 million at December 31, 2024 and 2023, respectively, and restricted cash of $ 176 million and $ 149 million at December 31, 2024 and 2023, respectively, and includes long-term restricted cash of $ 41 million and $ 174 million at December 31, 2024 and 2023, respectively, which is reported in Other deferred debits in the Consolidated Balance Sheets. | text | 174 | monetaryItemType | text: <entity> 174 </entity> <entity type> monetaryItemType </entity type> <context> Excludes cash of $ 219 million and $ 334 million at December 31, 2024 and 2023, respectively, and restricted cash of $ 176 million and $ 149 million at December 31, 2024 and 2023, respectively, and includes long-term restricted cash of $ 41 million and $ 174 million at December 31, 2024 and 2023, respectively, which is reported in Other deferred debits in the Consolidated Balance Sheets. </context> | us-gaap:CashAndCashEquivalentsFairValueDisclosure |
ComEd excludes cash of $ 66 million and $ 86 million at December 31, 2024 and 2023, respectively, and restricted cash of $ 176 million and $ 147 million at December 31, 2024 and 2023, respectively, and includes long-term restricted cash of $ 41 million and $ 174 million at December 31, 2024 and 2023, respectively, which is reported in Other deferred debits in the Consolidated Balance Sheets. PECO excludes cash of $ 19 million and $ 42 million at December 31, 2024 and 2023, respectively. BGE excludes cash of $ 33 million and $ 47 million at December 31, 2024 and 2023, respectively, and restricted cash of zero and $ 1 million at December 31, 2024 and 2023, respectively. | text | 66 | monetaryItemType | text: <entity> 66 </entity> <entity type> monetaryItemType </entity type> <context> ComEd excludes cash of $ 66 million and $ 86 million at December 31, 2024 and 2023, respectively, and restricted cash of $ 176 million and $ 147 million at December 31, 2024 and 2023, respectively, and includes long-term restricted cash of $ 41 million and $ 174 million at December 31, 2024 and 2023, respectively, which is reported in Other deferred debits in the Consolidated Balance Sheets. PECO excludes cash of $ 19 million and $ 42 million at December 31, 2024 and 2023, respectively. BGE excludes cash of $ 33 million and $ 47 million at December 31, 2024 and 2023, respectively, and restricted cash of zero and $ 1 million at December 31, 2024 and 2023, respectively. </context> | us-gaap:CashAndCashEquivalentsFairValueDisclosure |
ComEd excludes cash of $ 66 million and $ 86 million at December 31, 2024 and 2023, respectively, and restricted cash of $ 176 million and $ 147 million at December 31, 2024 and 2023, respectively, and includes long-term restricted cash of $ 41 million and $ 174 million at December 31, 2024 and 2023, respectively, which is reported in Other deferred debits in the Consolidated Balance Sheets. PECO excludes cash of $ 19 million and $ 42 million at December 31, 2024 and 2023, respectively. BGE excludes cash of $ 33 million and $ 47 million at December 31, 2024 and 2023, respectively, and restricted cash of zero and $ 1 million at December 31, 2024 and 2023, respectively. | text | 86 | monetaryItemType | text: <entity> 86 </entity> <entity type> monetaryItemType </entity type> <context> ComEd excludes cash of $ 66 million and $ 86 million at December 31, 2024 and 2023, respectively, and restricted cash of $ 176 million and $ 147 million at December 31, 2024 and 2023, respectively, and includes long-term restricted cash of $ 41 million and $ 174 million at December 31, 2024 and 2023, respectively, which is reported in Other deferred debits in the Consolidated Balance Sheets. PECO excludes cash of $ 19 million and $ 42 million at December 31, 2024 and 2023, respectively. BGE excludes cash of $ 33 million and $ 47 million at December 31, 2024 and 2023, respectively, and restricted cash of zero and $ 1 million at December 31, 2024 and 2023, respectively. </context> | us-gaap:CashAndCashEquivalentsFairValueDisclosure |
ComEd excludes cash of $ 66 million and $ 86 million at December 31, 2024 and 2023, respectively, and restricted cash of $ 176 million and $ 147 million at December 31, 2024 and 2023, respectively, and includes long-term restricted cash of $ 41 million and $ 174 million at December 31, 2024 and 2023, respectively, which is reported in Other deferred debits in the Consolidated Balance Sheets. PECO excludes cash of $ 19 million and $ 42 million at December 31, 2024 and 2023, respectively. BGE excludes cash of $ 33 million and $ 47 million at December 31, 2024 and 2023, respectively, and restricted cash of zero and $ 1 million at December 31, 2024 and 2023, respectively. | text | 176 | monetaryItemType | text: <entity> 176 </entity> <entity type> monetaryItemType </entity type> <context> ComEd excludes cash of $ 66 million and $ 86 million at December 31, 2024 and 2023, respectively, and restricted cash of $ 176 million and $ 147 million at December 31, 2024 and 2023, respectively, and includes long-term restricted cash of $ 41 million and $ 174 million at December 31, 2024 and 2023, respectively, which is reported in Other deferred debits in the Consolidated Balance Sheets. PECO excludes cash of $ 19 million and $ 42 million at December 31, 2024 and 2023, respectively. BGE excludes cash of $ 33 million and $ 47 million at December 31, 2024 and 2023, respectively, and restricted cash of zero and $ 1 million at December 31, 2024 and 2023, respectively. </context> | us-gaap:CashAndCashEquivalentsFairValueDisclosure |
ComEd excludes cash of $ 66 million and $ 86 million at December 31, 2024 and 2023, respectively, and restricted cash of $ 176 million and $ 147 million at December 31, 2024 and 2023, respectively, and includes long-term restricted cash of $ 41 million and $ 174 million at December 31, 2024 and 2023, respectively, which is reported in Other deferred debits in the Consolidated Balance Sheets. PECO excludes cash of $ 19 million and $ 42 million at December 31, 2024 and 2023, respectively. BGE excludes cash of $ 33 million and $ 47 million at December 31, 2024 and 2023, respectively, and restricted cash of zero and $ 1 million at December 31, 2024 and 2023, respectively. | text | 147 | monetaryItemType | text: <entity> 147 </entity> <entity type> monetaryItemType </entity type> <context> ComEd excludes cash of $ 66 million and $ 86 million at December 31, 2024 and 2023, respectively, and restricted cash of $ 176 million and $ 147 million at December 31, 2024 and 2023, respectively, and includes long-term restricted cash of $ 41 million and $ 174 million at December 31, 2024 and 2023, respectively, which is reported in Other deferred debits in the Consolidated Balance Sheets. PECO excludes cash of $ 19 million and $ 42 million at December 31, 2024 and 2023, respectively. BGE excludes cash of $ 33 million and $ 47 million at December 31, 2024 and 2023, respectively, and restricted cash of zero and $ 1 million at December 31, 2024 and 2023, respectively. </context> | us-gaap:CashAndCashEquivalentsFairValueDisclosure |
ComEd excludes cash of $ 66 million and $ 86 million at December 31, 2024 and 2023, respectively, and restricted cash of $ 176 million and $ 147 million at December 31, 2024 and 2023, respectively, and includes long-term restricted cash of $ 41 million and $ 174 million at December 31, 2024 and 2023, respectively, which is reported in Other deferred debits in the Consolidated Balance Sheets. PECO excludes cash of $ 19 million and $ 42 million at December 31, 2024 and 2023, respectively. BGE excludes cash of $ 33 million and $ 47 million at December 31, 2024 and 2023, respectively, and restricted cash of zero and $ 1 million at December 31, 2024 and 2023, respectively. | text | 41 | monetaryItemType | text: <entity> 41 </entity> <entity type> monetaryItemType </entity type> <context> ComEd excludes cash of $ 66 million and $ 86 million at December 31, 2024 and 2023, respectively, and restricted cash of $ 176 million and $ 147 million at December 31, 2024 and 2023, respectively, and includes long-term restricted cash of $ 41 million and $ 174 million at December 31, 2024 and 2023, respectively, which is reported in Other deferred debits in the Consolidated Balance Sheets. PECO excludes cash of $ 19 million and $ 42 million at December 31, 2024 and 2023, respectively. BGE excludes cash of $ 33 million and $ 47 million at December 31, 2024 and 2023, respectively, and restricted cash of zero and $ 1 million at December 31, 2024 and 2023, respectively. </context> | us-gaap:CashAndCashEquivalentsFairValueDisclosure |
ComEd excludes cash of $ 66 million and $ 86 million at December 31, 2024 and 2023, respectively, and restricted cash of $ 176 million and $ 147 million at December 31, 2024 and 2023, respectively, and includes long-term restricted cash of $ 41 million and $ 174 million at December 31, 2024 and 2023, respectively, which is reported in Other deferred debits in the Consolidated Balance Sheets. PECO excludes cash of $ 19 million and $ 42 million at December 31, 2024 and 2023, respectively. BGE excludes cash of $ 33 million and $ 47 million at December 31, 2024 and 2023, respectively, and restricted cash of zero and $ 1 million at December 31, 2024 and 2023, respectively. | text | 174 | monetaryItemType | text: <entity> 174 </entity> <entity type> monetaryItemType </entity type> <context> ComEd excludes cash of $ 66 million and $ 86 million at December 31, 2024 and 2023, respectively, and restricted cash of $ 176 million and $ 147 million at December 31, 2024 and 2023, respectively, and includes long-term restricted cash of $ 41 million and $ 174 million at December 31, 2024 and 2023, respectively, which is reported in Other deferred debits in the Consolidated Balance Sheets. PECO excludes cash of $ 19 million and $ 42 million at December 31, 2024 and 2023, respectively. BGE excludes cash of $ 33 million and $ 47 million at December 31, 2024 and 2023, respectively, and restricted cash of zero and $ 1 million at December 31, 2024 and 2023, respectively. </context> | us-gaap:CashAndCashEquivalentsFairValueDisclosure |
ComEd excludes cash of $ 66 million and $ 86 million at December 31, 2024 and 2023, respectively, and restricted cash of $ 176 million and $ 147 million at December 31, 2024 and 2023, respectively, and includes long-term restricted cash of $ 41 million and $ 174 million at December 31, 2024 and 2023, respectively, which is reported in Other deferred debits in the Consolidated Balance Sheets. PECO excludes cash of $ 19 million and $ 42 million at December 31, 2024 and 2023, respectively. BGE excludes cash of $ 33 million and $ 47 million at December 31, 2024 and 2023, respectively, and restricted cash of zero and $ 1 million at December 31, 2024 and 2023, respectively. | text | 19 | monetaryItemType | text: <entity> 19 </entity> <entity type> monetaryItemType </entity type> <context> ComEd excludes cash of $ 66 million and $ 86 million at December 31, 2024 and 2023, respectively, and restricted cash of $ 176 million and $ 147 million at December 31, 2024 and 2023, respectively, and includes long-term restricted cash of $ 41 million and $ 174 million at December 31, 2024 and 2023, respectively, which is reported in Other deferred debits in the Consolidated Balance Sheets. PECO excludes cash of $ 19 million and $ 42 million at December 31, 2024 and 2023, respectively. BGE excludes cash of $ 33 million and $ 47 million at December 31, 2024 and 2023, respectively, and restricted cash of zero and $ 1 million at December 31, 2024 and 2023, respectively. </context> | us-gaap:CashAndCashEquivalentsFairValueDisclosure |
ComEd excludes cash of $ 66 million and $ 86 million at December 31, 2024 and 2023, respectively, and restricted cash of $ 176 million and $ 147 million at December 31, 2024 and 2023, respectively, and includes long-term restricted cash of $ 41 million and $ 174 million at December 31, 2024 and 2023, respectively, which is reported in Other deferred debits in the Consolidated Balance Sheets. PECO excludes cash of $ 19 million and $ 42 million at December 31, 2024 and 2023, respectively. BGE excludes cash of $ 33 million and $ 47 million at December 31, 2024 and 2023, respectively, and restricted cash of zero and $ 1 million at December 31, 2024 and 2023, respectively. | text | 42 | monetaryItemType | text: <entity> 42 </entity> <entity type> monetaryItemType </entity type> <context> ComEd excludes cash of $ 66 million and $ 86 million at December 31, 2024 and 2023, respectively, and restricted cash of $ 176 million and $ 147 million at December 31, 2024 and 2023, respectively, and includes long-term restricted cash of $ 41 million and $ 174 million at December 31, 2024 and 2023, respectively, which is reported in Other deferred debits in the Consolidated Balance Sheets. PECO excludes cash of $ 19 million and $ 42 million at December 31, 2024 and 2023, respectively. BGE excludes cash of $ 33 million and $ 47 million at December 31, 2024 and 2023, respectively, and restricted cash of zero and $ 1 million at December 31, 2024 and 2023, respectively. </context> | us-gaap:CashAndCashEquivalentsFairValueDisclosure |
ComEd excludes cash of $ 66 million and $ 86 million at December 31, 2024 and 2023, respectively, and restricted cash of $ 176 million and $ 147 million at December 31, 2024 and 2023, respectively, and includes long-term restricted cash of $ 41 million and $ 174 million at December 31, 2024 and 2023, respectively, which is reported in Other deferred debits in the Consolidated Balance Sheets. PECO excludes cash of $ 19 million and $ 42 million at December 31, 2024 and 2023, respectively. BGE excludes cash of $ 33 million and $ 47 million at December 31, 2024 and 2023, respectively, and restricted cash of zero and $ 1 million at December 31, 2024 and 2023, respectively. | text | 33 | monetaryItemType | text: <entity> 33 </entity> <entity type> monetaryItemType </entity type> <context> ComEd excludes cash of $ 66 million and $ 86 million at December 31, 2024 and 2023, respectively, and restricted cash of $ 176 million and $ 147 million at December 31, 2024 and 2023, respectively, and includes long-term restricted cash of $ 41 million and $ 174 million at December 31, 2024 and 2023, respectively, which is reported in Other deferred debits in the Consolidated Balance Sheets. PECO excludes cash of $ 19 million and $ 42 million at December 31, 2024 and 2023, respectively. BGE excludes cash of $ 33 million and $ 47 million at December 31, 2024 and 2023, respectively, and restricted cash of zero and $ 1 million at December 31, 2024 and 2023, respectively. </context> | us-gaap:CashAndCashEquivalentsFairValueDisclosure |
ComEd excludes cash of $ 66 million and $ 86 million at December 31, 2024 and 2023, respectively, and restricted cash of $ 176 million and $ 147 million at December 31, 2024 and 2023, respectively, and includes long-term restricted cash of $ 41 million and $ 174 million at December 31, 2024 and 2023, respectively, which is reported in Other deferred debits in the Consolidated Balance Sheets. PECO excludes cash of $ 19 million and $ 42 million at December 31, 2024 and 2023, respectively. BGE excludes cash of $ 33 million and $ 47 million at December 31, 2024 and 2023, respectively, and restricted cash of zero and $ 1 million at December 31, 2024 and 2023, respectively. | text | 47 | monetaryItemType | text: <entity> 47 </entity> <entity type> monetaryItemType </entity type> <context> ComEd excludes cash of $ 66 million and $ 86 million at December 31, 2024 and 2023, respectively, and restricted cash of $ 176 million and $ 147 million at December 31, 2024 and 2023, respectively, and includes long-term restricted cash of $ 41 million and $ 174 million at December 31, 2024 and 2023, respectively, which is reported in Other deferred debits in the Consolidated Balance Sheets. PECO excludes cash of $ 19 million and $ 42 million at December 31, 2024 and 2023, respectively. BGE excludes cash of $ 33 million and $ 47 million at December 31, 2024 and 2023, respectively, and restricted cash of zero and $ 1 million at December 31, 2024 and 2023, respectively. </context> | us-gaap:CashAndCashEquivalentsFairValueDisclosure |
ComEd excludes cash of $ 66 million and $ 86 million at December 31, 2024 and 2023, respectively, and restricted cash of $ 176 million and $ 147 million at December 31, 2024 and 2023, respectively, and includes long-term restricted cash of $ 41 million and $ 174 million at December 31, 2024 and 2023, respectively, which is reported in Other deferred debits in the Consolidated Balance Sheets. PECO excludes cash of $ 19 million and $ 42 million at December 31, 2024 and 2023, respectively. BGE excludes cash of $ 33 million and $ 47 million at December 31, 2024 and 2023, respectively, and restricted cash of zero and $ 1 million at December 31, 2024 and 2023, respectively. | text | zero | monetaryItemType | text: <entity> zero </entity> <entity type> monetaryItemType </entity type> <context> ComEd excludes cash of $ 66 million and $ 86 million at December 31, 2024 and 2023, respectively, and restricted cash of $ 176 million and $ 147 million at December 31, 2024 and 2023, respectively, and includes long-term restricted cash of $ 41 million and $ 174 million at December 31, 2024 and 2023, respectively, which is reported in Other deferred debits in the Consolidated Balance Sheets. PECO excludes cash of $ 19 million and $ 42 million at December 31, 2024 and 2023, respectively. BGE excludes cash of $ 33 million and $ 47 million at December 31, 2024 and 2023, respectively, and restricted cash of zero and $ 1 million at December 31, 2024 and 2023, respectively. </context> | us-gaap:CashAndCashEquivalentsFairValueDisclosure |
ComEd excludes cash of $ 66 million and $ 86 million at December 31, 2024 and 2023, respectively, and restricted cash of $ 176 million and $ 147 million at December 31, 2024 and 2023, respectively, and includes long-term restricted cash of $ 41 million and $ 174 million at December 31, 2024 and 2023, respectively, which is reported in Other deferred debits in the Consolidated Balance Sheets. PECO excludes cash of $ 19 million and $ 42 million at December 31, 2024 and 2023, respectively. BGE excludes cash of $ 33 million and $ 47 million at December 31, 2024 and 2023, respectively, and restricted cash of zero and $ 1 million at December 31, 2024 and 2023, respectively. | text | 1 | monetaryItemType | text: <entity> 1 </entity> <entity type> monetaryItemType </entity type> <context> ComEd excludes cash of $ 66 million and $ 86 million at December 31, 2024 and 2023, respectively, and restricted cash of $ 176 million and $ 147 million at December 31, 2024 and 2023, respectively, and includes long-term restricted cash of $ 41 million and $ 174 million at December 31, 2024 and 2023, respectively, which is reported in Other deferred debits in the Consolidated Balance Sheets. PECO excludes cash of $ 19 million and $ 42 million at December 31, 2024 and 2023, respectively. BGE excludes cash of $ 33 million and $ 47 million at December 31, 2024 and 2023, respectively, and restricted cash of zero and $ 1 million at December 31, 2024 and 2023, respectively. </context> | us-gaap:CashAndCashEquivalentsFairValueDisclosure |
The Level 3 balance consists of the current and noncurrent liability of $ 29 million and $ 103 million, respectively, at December 31, 2024, and $ 27 million and $ 106 million, respectively, at December 31, 2023 related to floating-to-fixed energy swap contracts with unaffiliated suppliers. | text | 29 | monetaryItemType | text: <entity> 29 </entity> <entity type> monetaryItemType </entity type> <context> The Level 3 balance consists of the current and noncurrent liability of $ 29 million and $ 103 million, respectively, at December 31, 2024, and $ 27 million and $ 106 million, respectively, at December 31, 2023 related to floating-to-fixed energy swap contracts with unaffiliated suppliers. </context> | us-gaap:DerivativeLiabilitiesCurrent |
The Level 3 balance consists of the current and noncurrent liability of $ 29 million and $ 103 million, respectively, at December 31, 2024, and $ 27 million and $ 106 million, respectively, at December 31, 2023 related to floating-to-fixed energy swap contracts with unaffiliated suppliers. | text | 103 | monetaryItemType | text: <entity> 103 </entity> <entity type> monetaryItemType </entity type> <context> The Level 3 balance consists of the current and noncurrent liability of $ 29 million and $ 103 million, respectively, at December 31, 2024, and $ 27 million and $ 106 million, respectively, at December 31, 2023 related to floating-to-fixed energy swap contracts with unaffiliated suppliers. </context> | us-gaap:DerivativeLiabilitiesNoncurrent |
The Level 3 balance consists of the current and noncurrent liability of $ 29 million and $ 103 million, respectively, at December 31, 2024, and $ 27 million and $ 106 million, respectively, at December 31, 2023 related to floating-to-fixed energy swap contracts with unaffiliated suppliers. | text | 27 | monetaryItemType | text: <entity> 27 </entity> <entity type> monetaryItemType </entity type> <context> The Level 3 balance consists of the current and noncurrent liability of $ 29 million and $ 103 million, respectively, at December 31, 2024, and $ 27 million and $ 106 million, respectively, at December 31, 2023 related to floating-to-fixed energy swap contracts with unaffiliated suppliers. </context> | us-gaap:DerivativeLiabilitiesCurrent |
The Level 3 balance consists of the current and noncurrent liability of $ 29 million and $ 103 million, respectively, at December 31, 2024, and $ 27 million and $ 106 million, respectively, at December 31, 2023 related to floating-to-fixed energy swap contracts with unaffiliated suppliers. | text | 106 | monetaryItemType | text: <entity> 106 </entity> <entity type> monetaryItemType </entity type> <context> The Level 3 balance consists of the current and noncurrent liability of $ 29 million and $ 103 million, respectively, at December 31, 2024, and $ 27 million and $ 106 million, respectively, at December 31, 2023 related to floating-to-fixed energy swap contracts with unaffiliated suppliers. </context> | us-gaap:DerivativeLiabilitiesNoncurrent |
PHI excludes cash of $ 70 million and $ 96 million at December 31, 2024 and 2023, respectively, and restricted cash of zero and $ 1 million at December 31, 2024 and 2023, respectively. Pepco excludes cash of $ 30 million and $ 48 million at December 31, 2024 and 2023, respectively, and restricted cash of zero and $ 1 million at December 31, 2024 and 2023, respectively. DPL excludes cash of $ 20 million and $ 15 million at December 31, 2024 and 2023, respectively. ACE excludes cash of $ 14 million and $ 21 million at December 31, 2024 and 2023, respectively. | text | 70 | monetaryItemType | text: <entity> 70 </entity> <entity type> monetaryItemType </entity type> <context> PHI excludes cash of $ 70 million and $ 96 million at December 31, 2024 and 2023, respectively, and restricted cash of zero and $ 1 million at December 31, 2024 and 2023, respectively. Pepco excludes cash of $ 30 million and $ 48 million at December 31, 2024 and 2023, respectively, and restricted cash of zero and $ 1 million at December 31, 2024 and 2023, respectively. DPL excludes cash of $ 20 million and $ 15 million at December 31, 2024 and 2023, respectively. ACE excludes cash of $ 14 million and $ 21 million at December 31, 2024 and 2023, respectively. </context> | us-gaap:CashAndCashEquivalentsFairValueDisclosure |
PHI excludes cash of $ 70 million and $ 96 million at December 31, 2024 and 2023, respectively, and restricted cash of zero and $ 1 million at December 31, 2024 and 2023, respectively. Pepco excludes cash of $ 30 million and $ 48 million at December 31, 2024 and 2023, respectively, and restricted cash of zero and $ 1 million at December 31, 2024 and 2023, respectively. DPL excludes cash of $ 20 million and $ 15 million at December 31, 2024 and 2023, respectively. ACE excludes cash of $ 14 million and $ 21 million at December 31, 2024 and 2023, respectively. | text | 96 | monetaryItemType | text: <entity> 96 </entity> <entity type> monetaryItemType </entity type> <context> PHI excludes cash of $ 70 million and $ 96 million at December 31, 2024 and 2023, respectively, and restricted cash of zero and $ 1 million at December 31, 2024 and 2023, respectively. Pepco excludes cash of $ 30 million and $ 48 million at December 31, 2024 and 2023, respectively, and restricted cash of zero and $ 1 million at December 31, 2024 and 2023, respectively. DPL excludes cash of $ 20 million and $ 15 million at December 31, 2024 and 2023, respectively. ACE excludes cash of $ 14 million and $ 21 million at December 31, 2024 and 2023, respectively. </context> | us-gaap:CashAndCashEquivalentsFairValueDisclosure |
PHI excludes cash of $ 70 million and $ 96 million at December 31, 2024 and 2023, respectively, and restricted cash of zero and $ 1 million at December 31, 2024 and 2023, respectively. Pepco excludes cash of $ 30 million and $ 48 million at December 31, 2024 and 2023, respectively, and restricted cash of zero and $ 1 million at December 31, 2024 and 2023, respectively. DPL excludes cash of $ 20 million and $ 15 million at December 31, 2024 and 2023, respectively. ACE excludes cash of $ 14 million and $ 21 million at December 31, 2024 and 2023, respectively. | text | zero | monetaryItemType | text: <entity> zero </entity> <entity type> monetaryItemType </entity type> <context> PHI excludes cash of $ 70 million and $ 96 million at December 31, 2024 and 2023, respectively, and restricted cash of zero and $ 1 million at December 31, 2024 and 2023, respectively. Pepco excludes cash of $ 30 million and $ 48 million at December 31, 2024 and 2023, respectively, and restricted cash of zero and $ 1 million at December 31, 2024 and 2023, respectively. DPL excludes cash of $ 20 million and $ 15 million at December 31, 2024 and 2023, respectively. ACE excludes cash of $ 14 million and $ 21 million at December 31, 2024 and 2023, respectively. </context> | us-gaap:CashAndCashEquivalentsFairValueDisclosure |
PHI excludes cash of $ 70 million and $ 96 million at December 31, 2024 and 2023, respectively, and restricted cash of zero and $ 1 million at December 31, 2024 and 2023, respectively. Pepco excludes cash of $ 30 million and $ 48 million at December 31, 2024 and 2023, respectively, and restricted cash of zero and $ 1 million at December 31, 2024 and 2023, respectively. DPL excludes cash of $ 20 million and $ 15 million at December 31, 2024 and 2023, respectively. ACE excludes cash of $ 14 million and $ 21 million at December 31, 2024 and 2023, respectively. | text | 1 | monetaryItemType | text: <entity> 1 </entity> <entity type> monetaryItemType </entity type> <context> PHI excludes cash of $ 70 million and $ 96 million at December 31, 2024 and 2023, respectively, and restricted cash of zero and $ 1 million at December 31, 2024 and 2023, respectively. Pepco excludes cash of $ 30 million and $ 48 million at December 31, 2024 and 2023, respectively, and restricted cash of zero and $ 1 million at December 31, 2024 and 2023, respectively. DPL excludes cash of $ 20 million and $ 15 million at December 31, 2024 and 2023, respectively. ACE excludes cash of $ 14 million and $ 21 million at December 31, 2024 and 2023, respectively. </context> | us-gaap:CashAndCashEquivalentsFairValueDisclosure |
PHI excludes cash of $ 70 million and $ 96 million at December 31, 2024 and 2023, respectively, and restricted cash of zero and $ 1 million at December 31, 2024 and 2023, respectively. Pepco excludes cash of $ 30 million and $ 48 million at December 31, 2024 and 2023, respectively, and restricted cash of zero and $ 1 million at December 31, 2024 and 2023, respectively. DPL excludes cash of $ 20 million and $ 15 million at December 31, 2024 and 2023, respectively. ACE excludes cash of $ 14 million and $ 21 million at December 31, 2024 and 2023, respectively. | text | 30 | monetaryItemType | text: <entity> 30 </entity> <entity type> monetaryItemType </entity type> <context> PHI excludes cash of $ 70 million and $ 96 million at December 31, 2024 and 2023, respectively, and restricted cash of zero and $ 1 million at December 31, 2024 and 2023, respectively. Pepco excludes cash of $ 30 million and $ 48 million at December 31, 2024 and 2023, respectively, and restricted cash of zero and $ 1 million at December 31, 2024 and 2023, respectively. DPL excludes cash of $ 20 million and $ 15 million at December 31, 2024 and 2023, respectively. ACE excludes cash of $ 14 million and $ 21 million at December 31, 2024 and 2023, respectively. </context> | us-gaap:CashAndCashEquivalentsFairValueDisclosure |
PHI excludes cash of $ 70 million and $ 96 million at December 31, 2024 and 2023, respectively, and restricted cash of zero and $ 1 million at December 31, 2024 and 2023, respectively. Pepco excludes cash of $ 30 million and $ 48 million at December 31, 2024 and 2023, respectively, and restricted cash of zero and $ 1 million at December 31, 2024 and 2023, respectively. DPL excludes cash of $ 20 million and $ 15 million at December 31, 2024 and 2023, respectively. ACE excludes cash of $ 14 million and $ 21 million at December 31, 2024 and 2023, respectively. | text | 48 | monetaryItemType | text: <entity> 48 </entity> <entity type> monetaryItemType </entity type> <context> PHI excludes cash of $ 70 million and $ 96 million at December 31, 2024 and 2023, respectively, and restricted cash of zero and $ 1 million at December 31, 2024 and 2023, respectively. Pepco excludes cash of $ 30 million and $ 48 million at December 31, 2024 and 2023, respectively, and restricted cash of zero and $ 1 million at December 31, 2024 and 2023, respectively. DPL excludes cash of $ 20 million and $ 15 million at December 31, 2024 and 2023, respectively. ACE excludes cash of $ 14 million and $ 21 million at December 31, 2024 and 2023, respectively. </context> | us-gaap:CashAndCashEquivalentsFairValueDisclosure |
PHI excludes cash of $ 70 million and $ 96 million at December 31, 2024 and 2023, respectively, and restricted cash of zero and $ 1 million at December 31, 2024 and 2023, respectively. Pepco excludes cash of $ 30 million and $ 48 million at December 31, 2024 and 2023, respectively, and restricted cash of zero and $ 1 million at December 31, 2024 and 2023, respectively. DPL excludes cash of $ 20 million and $ 15 million at December 31, 2024 and 2023, respectively. ACE excludes cash of $ 14 million and $ 21 million at December 31, 2024 and 2023, respectively. | text | 20 | monetaryItemType | text: <entity> 20 </entity> <entity type> monetaryItemType </entity type> <context> PHI excludes cash of $ 70 million and $ 96 million at December 31, 2024 and 2023, respectively, and restricted cash of zero and $ 1 million at December 31, 2024 and 2023, respectively. Pepco excludes cash of $ 30 million and $ 48 million at December 31, 2024 and 2023, respectively, and restricted cash of zero and $ 1 million at December 31, 2024 and 2023, respectively. DPL excludes cash of $ 20 million and $ 15 million at December 31, 2024 and 2023, respectively. ACE excludes cash of $ 14 million and $ 21 million at December 31, 2024 and 2023, respectively. </context> | us-gaap:CashAndCashEquivalentsFairValueDisclosure |
PHI excludes cash of $ 70 million and $ 96 million at December 31, 2024 and 2023, respectively, and restricted cash of zero and $ 1 million at December 31, 2024 and 2023, respectively. Pepco excludes cash of $ 30 million and $ 48 million at December 31, 2024 and 2023, respectively, and restricted cash of zero and $ 1 million at December 31, 2024 and 2023, respectively. DPL excludes cash of $ 20 million and $ 15 million at December 31, 2024 and 2023, respectively. ACE excludes cash of $ 14 million and $ 21 million at December 31, 2024 and 2023, respectively. | text | 15 | monetaryItemType | text: <entity> 15 </entity> <entity type> monetaryItemType </entity type> <context> PHI excludes cash of $ 70 million and $ 96 million at December 31, 2024 and 2023, respectively, and restricted cash of zero and $ 1 million at December 31, 2024 and 2023, respectively. Pepco excludes cash of $ 30 million and $ 48 million at December 31, 2024 and 2023, respectively, and restricted cash of zero and $ 1 million at December 31, 2024 and 2023, respectively. DPL excludes cash of $ 20 million and $ 15 million at December 31, 2024 and 2023, respectively. ACE excludes cash of $ 14 million and $ 21 million at December 31, 2024 and 2023, respectively. </context> | us-gaap:CashAndCashEquivalentsFairValueDisclosure |
PHI excludes cash of $ 70 million and $ 96 million at December 31, 2024 and 2023, respectively, and restricted cash of zero and $ 1 million at December 31, 2024 and 2023, respectively. Pepco excludes cash of $ 30 million and $ 48 million at December 31, 2024 and 2023, respectively, and restricted cash of zero and $ 1 million at December 31, 2024 and 2023, respectively. DPL excludes cash of $ 20 million and $ 15 million at December 31, 2024 and 2023, respectively. ACE excludes cash of $ 14 million and $ 21 million at December 31, 2024 and 2023, respectively. | text | 14 | monetaryItemType | text: <entity> 14 </entity> <entity type> monetaryItemType </entity type> <context> PHI excludes cash of $ 70 million and $ 96 million at December 31, 2024 and 2023, respectively, and restricted cash of zero and $ 1 million at December 31, 2024 and 2023, respectively. Pepco excludes cash of $ 30 million and $ 48 million at December 31, 2024 and 2023, respectively, and restricted cash of zero and $ 1 million at December 31, 2024 and 2023, respectively. DPL excludes cash of $ 20 million and $ 15 million at December 31, 2024 and 2023, respectively. ACE excludes cash of $ 14 million and $ 21 million at December 31, 2024 and 2023, respectively. </context> | us-gaap:CashAndCashEquivalentsFairValueDisclosure |
PHI excludes cash of $ 70 million and $ 96 million at December 31, 2024 and 2023, respectively, and restricted cash of zero and $ 1 million at December 31, 2024 and 2023, respectively. Pepco excludes cash of $ 30 million and $ 48 million at December 31, 2024 and 2023, respectively, and restricted cash of zero and $ 1 million at December 31, 2024 and 2023, respectively. DPL excludes cash of $ 20 million and $ 15 million at December 31, 2024 and 2023, respectively. ACE excludes cash of $ 14 million and $ 21 million at December 31, 2024 and 2023, respectively. | text | 21 | monetaryItemType | text: <entity> 21 </entity> <entity type> monetaryItemType </entity type> <context> PHI excludes cash of $ 70 million and $ 96 million at December 31, 2024 and 2023, respectively, and restricted cash of zero and $ 1 million at December 31, 2024 and 2023, respectively. Pepco excludes cash of $ 30 million and $ 48 million at December 31, 2024 and 2023, respectively, and restricted cash of zero and $ 1 million at December 31, 2024 and 2023, respectively. DPL excludes cash of $ 20 million and $ 15 million at December 31, 2024 and 2023, respectively. ACE excludes cash of $ 14 million and $ 21 million at December 31, 2024 and 2023, respectively. </context> | us-gaap:CashAndCashEquivalentsFairValueDisclosure |
Includes $ 40 million of decreases in fair value and an increase for realized gains due to settlements of $ 40 million recorded in Purchased power expense associated with floating-to-fixed energy swap contracts with unaffiliated suppliers for the year ended December 31, 2024. Includes $ 83 million of decreases in fair value and an increase for realized gains due to settlements of $ 34 million recorded in Purchased power expense associated with floating-to-fixed energy swap contracts with unaffiliated suppliers for the year ended December 31, 2023. | text | 40 | monetaryItemType | text: <entity> 40 </entity> <entity type> monetaryItemType </entity type> <context> Includes $ 40 million of decreases in fair value and an increase for realized gains due to settlements of $ 40 million recorded in Purchased power expense associated with floating-to-fixed energy swap contracts with unaffiliated suppliers for the year ended December 31, 2024. Includes $ 83 million of decreases in fair value and an increase for realized gains due to settlements of $ 34 million recorded in Purchased power expense associated with floating-to-fixed energy swap contracts with unaffiliated suppliers for the year ended December 31, 2023. </context> | us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease |
Includes $ 40 million of decreases in fair value and an increase for realized gains due to settlements of $ 40 million recorded in Purchased power expense associated with floating-to-fixed energy swap contracts with unaffiliated suppliers for the year ended December 31, 2024. Includes $ 83 million of decreases in fair value and an increase for realized gains due to settlements of $ 34 million recorded in Purchased power expense associated with floating-to-fixed energy swap contracts with unaffiliated suppliers for the year ended December 31, 2023. | text | 40 | monetaryItemType | text: <entity> 40 </entity> <entity type> monetaryItemType </entity type> <context> Includes $ 40 million of decreases in fair value and an increase for realized gains due to settlements of $ 40 million recorded in Purchased power expense associated with floating-to-fixed energy swap contracts with unaffiliated suppliers for the year ended December 31, 2024. Includes $ 83 million of decreases in fair value and an increase for realized gains due to settlements of $ 34 million recorded in Purchased power expense associated with floating-to-fixed energy swap contracts with unaffiliated suppliers for the year ended December 31, 2023. </context> | us-gaap:RealizedInvestmentGainsLosses |
Includes $ 40 million of decreases in fair value and an increase for realized gains due to settlements of $ 40 million recorded in Purchased power expense associated with floating-to-fixed energy swap contracts with unaffiliated suppliers for the year ended December 31, 2024. Includes $ 83 million of decreases in fair value and an increase for realized gains due to settlements of $ 34 million recorded in Purchased power expense associated with floating-to-fixed energy swap contracts with unaffiliated suppliers for the year ended December 31, 2023. | text | 83 | monetaryItemType | text: <entity> 83 </entity> <entity type> monetaryItemType </entity type> <context> Includes $ 40 million of decreases in fair value and an increase for realized gains due to settlements of $ 40 million recorded in Purchased power expense associated with floating-to-fixed energy swap contracts with unaffiliated suppliers for the year ended December 31, 2024. Includes $ 83 million of decreases in fair value and an increase for realized gains due to settlements of $ 34 million recorded in Purchased power expense associated with floating-to-fixed energy swap contracts with unaffiliated suppliers for the year ended December 31, 2023. </context> | us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease |
Includes $ 40 million of decreases in fair value and an increase for realized gains due to settlements of $ 40 million recorded in Purchased power expense associated with floating-to-fixed energy swap contracts with unaffiliated suppliers for the year ended December 31, 2024. Includes $ 83 million of decreases in fair value and an increase for realized gains due to settlements of $ 34 million recorded in Purchased power expense associated with floating-to-fixed energy swap contracts with unaffiliated suppliers for the year ended December 31, 2023. | text | 34 | monetaryItemType | text: <entity> 34 </entity> <entity type> monetaryItemType </entity type> <context> Includes $ 40 million of decreases in fair value and an increase for realized gains due to settlements of $ 40 million recorded in Purchased power expense associated with floating-to-fixed energy swap contracts with unaffiliated suppliers for the year ended December 31, 2024. Includes $ 83 million of decreases in fair value and an increase for realized gains due to settlements of $ 34 million recorded in Purchased power expense associated with floating-to-fixed energy swap contracts with unaffiliated suppliers for the year ended December 31, 2023. </context> | us-gaap:RealizedInvestmentGainsLosses |
The balance of the current and noncurrent asset was effectively zero as of December 31, 2024. The balance consists of a current and noncurrent liability of $ 29 million and $ 103 million, respectively, as of December 31, 2024. | text | zero | monetaryItemType | text: <entity> zero </entity> <entity type> monetaryItemType </entity type> <context> The balance of the current and noncurrent asset was effectively zero as of December 31, 2024. The balance consists of a current and noncurrent liability of $ 29 million and $ 103 million, respectively, as of December 31, 2024. </context> | us-gaap:DerivativeAssets |
The balance of the current and noncurrent asset was effectively zero as of December 31, 2024. The balance consists of a current and noncurrent liability of $ 29 million and $ 103 million, respectively, as of December 31, 2024. | text | 29 | monetaryItemType | text: <entity> 29 </entity> <entity type> monetaryItemType </entity type> <context> The balance of the current and noncurrent asset was effectively zero as of December 31, 2024. The balance consists of a current and noncurrent liability of $ 29 million and $ 103 million, respectively, as of December 31, 2024. </context> | us-gaap:DerivativeLiabilitiesCurrent |
The balance of the current and noncurrent asset was effectively zero as of December 31, 2024. The balance consists of a current and noncurrent liability of $ 29 million and $ 103 million, respectively, as of December 31, 2024. | text | 103 | monetaryItemType | text: <entity> 103 </entity> <entity type> monetaryItemType </entity type> <context> The balance of the current and noncurrent asset was effectively zero as of December 31, 2024. The balance consists of a current and noncurrent liability of $ 29 million and $ 103 million, respectively, as of December 31, 2024. </context> | us-gaap:DerivativeLiabilitiesNoncurrent |
Represents the maximum potential obligation in the event the fair value of certain leased equipment and fleet vehicles is zero at the end of the maximum lease term. The lease term associated with these assets ranges from 1 to 8 years. The maximum potential obligation at the end of the minimum lease term would be $ 60 million guaranteed by Exelon and PHI, of which $ 20 million | text | 20 | monetaryItemType | text: <entity> 20 </entity> <entity type> monetaryItemType </entity type> <context> Represents the maximum potential obligation in the event the fair value of certain leased equipment and fleet vehicles is zero at the end of the maximum lease term. The lease term associated with these assets ranges from 1 to 8 years. The maximum potential obligation at the end of the minimum lease term would be $ 60 million guaranteed by Exelon and PHI, of which $ 20 million </context> | us-gaap:GuaranteeObligationsMaximumExposure |
$ 23 million, and $ 17 million is guaranteed by Pepco, DPL, and ACE, respectively. Historically, payments under the guarantees have not been made and PHI believes the likelihood of payments being required under the guarantees is remote. | text | 23 | monetaryItemType | text: <entity> 23 </entity> <entity type> monetaryItemType </entity type> <context> $ 23 million, and $ 17 million is guaranteed by Pepco, DPL, and ACE, respectively. Historically, payments under the guarantees have not been made and PHI believes the likelihood of payments being required under the guarantees is remote. </context> | us-gaap:GuaranteeObligationsMaximumExposure |
$ 23 million, and $ 17 million is guaranteed by Pepco, DPL, and ACE, respectively. Historically, payments under the guarantees have not been made and PHI believes the likelihood of payments being required under the guarantees is remote. | text | 17 | monetaryItemType | text: <entity> 17 </entity> <entity type> monetaryItemType </entity type> <context> $ 23 million, and $ 17 million is guaranteed by Pepco, DPL, and ACE, respectively. Historically, payments under the guarantees have not been made and PHI believes the likelihood of payments being required under the guarantees is remote. </context> | us-gaap:GuaranteeObligationsMaximumExposure |
In 2024, ComEd and PECO completed an annual study of their future estimated MGP remediation requirements. The study resulted in increases of $ 13 million and $ 4 million | text | 13 | monetaryItemType | text: <entity> 13 </entity> <entity type> monetaryItemType </entity type> <context> In 2024, ComEd and PECO completed an annual study of their future estimated MGP remediation requirements. The study resulted in increases of $ 13 million and $ 4 million </context> | us-gaap:AccrualForEnvironmentalLossContingenciesPeriodIncreaseDecrease |
In 2024, ComEd and PECO completed an annual study of their future estimated MGP remediation requirements. The study resulted in increases of $ 13 million and $ 4 million | text | 4 | monetaryItemType | text: <entity> 4 </entity> <entity type> monetaryItemType </entity type> <context> In 2024, ComEd and PECO completed an annual study of their future estimated MGP remediation requirements. The study resulted in increases of $ 13 million and $ 4 million </context> | us-gaap:AccrualForEnvironmentalLossContingenciesPeriodIncreaseDecrease |
that it had also opened an investigation into their lobbying activities. On July 17, 2020, ComEd entered into a DPA with the USAO to resolve the USAO investigation, which included a payment to the U.S. Treasury of $ 200 million, which was paid in November 2020. The three-year term of the DPA ended on July 17, 2023, and on that same date the court granted the USAO’s motion to dismiss the pending charge against ComEd that had been deferred by the DPA. | text | 200 | monetaryItemType | text: <entity> 200 </entity> <entity type> monetaryItemType </entity type> <context> that it had also opened an investigation into their lobbying activities. On July 17, 2020, ComEd entered into a DPA with the USAO to resolve the USAO investigation, which included a payment to the U.S. Treasury of $ 200 million, which was paid in November 2020. The three-year term of the DPA ended on July 17, 2023, and on that same date the court granted the USAO’s motion to dismiss the pending charge against ComEd that had been deferred by the DPA. </context> | us-gaap:LitigationSettlementAmountAwardedToOtherParty |
On September 28, 2023, Exelon and ComEd reached a settlement with the SEC, concluding and resolving in its entirety the SEC investigation, which related to the conduct identified in the DPA that was entered into by ComEd in July 2020 and successfully exited in July 2023. Under the terms of the settlement, Exelon agreed to pay a civil penalty of $ 46.2 million and Exelon and ComEd agreed to cease and desist from committing or causing any violations and any future violations of specified provisions of the federal securities laws and rules promulgated thereunder. Exelon recorded an expense and paid the full amount of the penalty in 2023, which was reflected in Operating and maintenance expense within Exelon's Consolidated Statements of Operations and Comprehensive Income. | text | 46.2 | monetaryItemType | text: <entity> 46.2 </entity> <entity type> monetaryItemType </entity type> <context> On September 28, 2023, Exelon and ComEd reached a settlement with the SEC, concluding and resolving in its entirety the SEC investigation, which related to the conduct identified in the DPA that was entered into by ComEd in July 2020 and successfully exited in July 2023. Under the terms of the settlement, Exelon agreed to pay a civil penalty of $ 46.2 million and Exelon and ComEd agreed to cease and desist from committing or causing any violations and any future violations of specified provisions of the federal securities laws and rules promulgated thereunder. Exelon recorded an expense and paid the full amount of the penalty in 2023, which was reflected in Operating and maintenance expense within Exelon's Consolidated Statements of Operations and Comprehensive Income. </context> | us-gaap:LossContingencyAccrualAtCarryingValue |
In August 2022, the ICC concluded its investigation initiated on August 12, 2021 into rate impacts of conduct admitted in the DPA, including the costs recovered from customers related to the DPA and Exelon's funding of the fine paid by ComEd. On August 17, 2022, the ICC issued its final order accepting ComEd's voluntary customer refund offer of approximately $ 38 million (of which about $ 31 million was ICC jurisdictional; the remaining balance was FERC jurisdictional) that resolved the question of whether customer funds were used for DPA related activities. The customer refund included the cost of every individual or entity that was either (i) identified in the DPA or (ii) identified by ComEd as an associate of the former Speaker of the Illinois House of Representatives in the ICC proceeding. The ICC’s DPA investigation is now closed. The ICC jurisdictional refund was made to customers during the April 2023 billing cycle, as required by the ICC. The FERC jurisdictional refund was completed as of May 2024 as part of ComEd's transmission formula rate update proceeding, submitted on May 12, 2023. The customer refund was not recovered in rates or charged to customers and ComEd will not seek or accept reimbursement or indemnification from any source other than Exelon. | text | 38 | monetaryItemType | text: <entity> 38 </entity> <entity type> monetaryItemType </entity type> <context> In August 2022, the ICC concluded its investigation initiated on August 12, 2021 into rate impacts of conduct admitted in the DPA, including the costs recovered from customers related to the DPA and Exelon's funding of the fine paid by ComEd. On August 17, 2022, the ICC issued its final order accepting ComEd's voluntary customer refund offer of approximately $ 38 million (of which about $ 31 million was ICC jurisdictional; the remaining balance was FERC jurisdictional) that resolved the question of whether customer funds were used for DPA related activities. The customer refund included the cost of every individual or entity that was either (i) identified in the DPA or (ii) identified by ComEd as an associate of the former Speaker of the Illinois House of Representatives in the ICC proceeding. The ICC’s DPA investigation is now closed. The ICC jurisdictional refund was made to customers during the April 2023 billing cycle, as required by the ICC. The FERC jurisdictional refund was completed as of May 2024 as part of ComEd's transmission formula rate update proceeding, submitted on May 12, 2023. The customer refund was not recovered in rates or charged to customers and ComEd will not seek or accept reimbursement or indemnification from any source other than Exelon. </context> | us-gaap:CustomerRefundLiabilityCurrent |
In August 2022, the ICC concluded its investigation initiated on August 12, 2021 into rate impacts of conduct admitted in the DPA, including the costs recovered from customers related to the DPA and Exelon's funding of the fine paid by ComEd. On August 17, 2022, the ICC issued its final order accepting ComEd's voluntary customer refund offer of approximately $ 38 million (of which about $ 31 million was ICC jurisdictional; the remaining balance was FERC jurisdictional) that resolved the question of whether customer funds were used for DPA related activities. The customer refund included the cost of every individual or entity that was either (i) identified in the DPA or (ii) identified by ComEd as an associate of the former Speaker of the Illinois House of Representatives in the ICC proceeding. The ICC’s DPA investigation is now closed. The ICC jurisdictional refund was made to customers during the April 2023 billing cycle, as required by the ICC. The FERC jurisdictional refund was completed as of May 2024 as part of ComEd's transmission formula rate update proceeding, submitted on May 12, 2023. The customer refund was not recovered in rates or charged to customers and ComEd will not seek or accept reimbursement or indemnification from any source other than Exelon. | text | 31 | monetaryItemType | text: <entity> 31 </entity> <entity type> monetaryItemType </entity type> <context> In August 2022, the ICC concluded its investigation initiated on August 12, 2021 into rate impacts of conduct admitted in the DPA, including the costs recovered from customers related to the DPA and Exelon's funding of the fine paid by ComEd. On August 17, 2022, the ICC issued its final order accepting ComEd's voluntary customer refund offer of approximately $ 38 million (of which about $ 31 million was ICC jurisdictional; the remaining balance was FERC jurisdictional) that resolved the question of whether customer funds were used for DPA related activities. The customer refund included the cost of every individual or entity that was either (i) identified in the DPA or (ii) identified by ComEd as an associate of the former Speaker of the Illinois House of Representatives in the ICC proceeding. The ICC’s DPA investigation is now closed. The ICC jurisdictional refund was made to customers during the April 2023 billing cycle, as required by the ICC. The FERC jurisdictional refund was completed as of May 2024 as part of ComEd's transmission formula rate update proceeding, submitted on May 12, 2023. The customer refund was not recovered in rates or charged to customers and ComEd will not seek or accept reimbursement or indemnification from any source other than Exelon. </context> | us-gaap:CustomerRefundLiabilityCurrent |
Maryland imposes a 6% sales and use tax on the purchase of most goods and services. BGE, Pepco, and DPL have filed or plan to file protective refund claims, totaling an estimated $ 100 million, treating electric transmission and distribution machinery and equipment as nontaxable pursuant to the manufacturing exemption available under the Maryland sales and use tax law. The Maryland Comptroller has initially denied the refund claim and litigation is pending. | text | 100 | monetaryItemType | text: <entity> 100 </entity> <entity type> monetaryItemType </entity type> <context> Maryland imposes a 6% sales and use tax on the purchase of most goods and services. BGE, Pepco, and DPL have filed or plan to file protective refund claims, totaling an estimated $ 100 million, treating electric transmission and distribution machinery and equipment as nontaxable pursuant to the manufacturing exemption available under the Maryland sales and use tax law. The Maryland Comptroller has initially denied the refund claim and litigation is pending. </context> | us-gaap:IncomeTaxesReceivableNoncurrent |
In the event transmission and distribution equipment is determined to be exempt, Exelon, BGE, PHI, Pepco, and DPL will record estimated receivables of $ 100 million, $ 65 million, $ 35 million, $ 25 million, and $ 10 million, respectively. The sales tax payments were primarily capitalized; therefore, the refund would be recorded as a reduction to property, plant, and equipment included in rate base. | text | 100 | monetaryItemType | text: <entity> 100 </entity> <entity type> monetaryItemType </entity type> <context> In the event transmission and distribution equipment is determined to be exempt, Exelon, BGE, PHI, Pepco, and DPL will record estimated receivables of $ 100 million, $ 65 million, $ 35 million, $ 25 million, and $ 10 million, respectively. The sales tax payments were primarily capitalized; therefore, the refund would be recorded as a reduction to property, plant, and equipment included in rate base. </context> | us-gaap:IncomeTaxesReceivableNoncurrent |
In the event transmission and distribution equipment is determined to be exempt, Exelon, BGE, PHI, Pepco, and DPL will record estimated receivables of $ 100 million, $ 65 million, $ 35 million, $ 25 million, and $ 10 million, respectively. The sales tax payments were primarily capitalized; therefore, the refund would be recorded as a reduction to property, plant, and equipment included in rate base. | text | 65 | monetaryItemType | text: <entity> 65 </entity> <entity type> monetaryItemType </entity type> <context> In the event transmission and distribution equipment is determined to be exempt, Exelon, BGE, PHI, Pepco, and DPL will record estimated receivables of $ 100 million, $ 65 million, $ 35 million, $ 25 million, and $ 10 million, respectively. The sales tax payments were primarily capitalized; therefore, the refund would be recorded as a reduction to property, plant, and equipment included in rate base. </context> | us-gaap:IncomeTaxesReceivableNoncurrent |
In the event transmission and distribution equipment is determined to be exempt, Exelon, BGE, PHI, Pepco, and DPL will record estimated receivables of $ 100 million, $ 65 million, $ 35 million, $ 25 million, and $ 10 million, respectively. The sales tax payments were primarily capitalized; therefore, the refund would be recorded as a reduction to property, plant, and equipment included in rate base. | text | 35 | monetaryItemType | text: <entity> 35 </entity> <entity type> monetaryItemType </entity type> <context> In the event transmission and distribution equipment is determined to be exempt, Exelon, BGE, PHI, Pepco, and DPL will record estimated receivables of $ 100 million, $ 65 million, $ 35 million, $ 25 million, and $ 10 million, respectively. The sales tax payments were primarily capitalized; therefore, the refund would be recorded as a reduction to property, plant, and equipment included in rate base. </context> | us-gaap:IncomeTaxesReceivableNoncurrent |
In the event transmission and distribution equipment is determined to be exempt, Exelon, BGE, PHI, Pepco, and DPL will record estimated receivables of $ 100 million, $ 65 million, $ 35 million, $ 25 million, and $ 10 million, respectively. The sales tax payments were primarily capitalized; therefore, the refund would be recorded as a reduction to property, plant, and equipment included in rate base. | text | 25 | monetaryItemType | text: <entity> 25 </entity> <entity type> monetaryItemType </entity type> <context> In the event transmission and distribution equipment is determined to be exempt, Exelon, BGE, PHI, Pepco, and DPL will record estimated receivables of $ 100 million, $ 65 million, $ 35 million, $ 25 million, and $ 10 million, respectively. The sales tax payments were primarily capitalized; therefore, the refund would be recorded as a reduction to property, plant, and equipment included in rate base. </context> | us-gaap:IncomeTaxesReceivableNoncurrent |
In the event transmission and distribution equipment is determined to be exempt, Exelon, BGE, PHI, Pepco, and DPL will record estimated receivables of $ 100 million, $ 65 million, $ 35 million, $ 25 million, and $ 10 million, respectively. The sales tax payments were primarily capitalized; therefore, the refund would be recorded as a reduction to property, plant, and equipment included in rate base. | text | 10 | monetaryItemType | text: <entity> 10 </entity> <entity type> monetaryItemType </entity type> <context> In the event transmission and distribution equipment is determined to be exempt, Exelon, BGE, PHI, Pepco, and DPL will record estimated receivables of $ 100 million, $ 65 million, $ 35 million, $ 25 million, and $ 10 million, respectively. The sales tax payments were primarily capitalized; therefore, the refund would be recorded as a reduction to property, plant, and equipment included in rate base. </context> | us-gaap:IncomeTaxesReceivableNoncurrent |
On August 4, 2022, Exelon entered into an agreement with certain underwriters in connection with an underwritten public offering (the “Offering”) of 11.3 million shares (the “Shares”) of its Common stock, no par value (“Common Stock”). The Shares were sold to the underwriters at a price per share of $ 43.32 . Exelon also granted the underwriters an option to purchase an additional 1.695 million shares of Common stock also at the price per share of $ 43.32 . On August 5, 2022, the underwriters exercised the option in full. The net proceeds from the Offering and the exercise of the underwriters’ option were $ 563 million before expenses paid by Exelon. Exelon used the proceeds, together with available cash balances, to repay $ 575 million in borrowings under a $ 1.15 billion term loan credit facility. See Note 16 — Debt and Credit Agreements for additional information on Exelon’s term loan within our 2022 10-K. | text | 11.3 | sharesItemType | text: <entity> 11.3 </entity> <entity type> sharesItemType </entity type> <context> On August 4, 2022, Exelon entered into an agreement with certain underwriters in connection with an underwritten public offering (the “Offering”) of 11.3 million shares (the “Shares”) of its Common stock, no par value (“Common Stock”). The Shares were sold to the underwriters at a price per share of $ 43.32 . Exelon also granted the underwriters an option to purchase an additional 1.695 million shares of Common stock also at the price per share of $ 43.32 . On August 5, 2022, the underwriters exercised the option in full. The net proceeds from the Offering and the exercise of the underwriters’ option were $ 563 million before expenses paid by Exelon. Exelon used the proceeds, together with available cash balances, to repay $ 575 million in borrowings under a $ 1.15 billion term loan credit facility. See Note 16 — Debt and Credit Agreements for additional information on Exelon’s term loan within our 2022 10-K. </context> | us-gaap:StockIssuedDuringPeriodSharesNewIssues |
On August 4, 2022, Exelon entered into an agreement with certain underwriters in connection with an underwritten public offering (the “Offering”) of 11.3 million shares (the “Shares”) of its Common stock, no par value (“Common Stock”). The Shares were sold to the underwriters at a price per share of $ 43.32 . Exelon also granted the underwriters an option to purchase an additional 1.695 million shares of Common stock also at the price per share of $ 43.32 . On August 5, 2022, the underwriters exercised the option in full. The net proceeds from the Offering and the exercise of the underwriters’ option were $ 563 million before expenses paid by Exelon. Exelon used the proceeds, together with available cash balances, to repay $ 575 million in borrowings under a $ 1.15 billion term loan credit facility. See Note 16 — Debt and Credit Agreements for additional information on Exelon’s term loan within our 2022 10-K. | text | no | perShareItemType | text: <entity> no </entity> <entity type> perShareItemType </entity type> <context> On August 4, 2022, Exelon entered into an agreement with certain underwriters in connection with an underwritten public offering (the “Offering”) of 11.3 million shares (the “Shares”) of its Common stock, no par value (“Common Stock”). The Shares were sold to the underwriters at a price per share of $ 43.32 . Exelon also granted the underwriters an option to purchase an additional 1.695 million shares of Common stock also at the price per share of $ 43.32 . On August 5, 2022, the underwriters exercised the option in full. The net proceeds from the Offering and the exercise of the underwriters’ option were $ 563 million before expenses paid by Exelon. Exelon used the proceeds, together with available cash balances, to repay $ 575 million in borrowings under a $ 1.15 billion term loan credit facility. See Note 16 — Debt and Credit Agreements for additional information on Exelon’s term loan within our 2022 10-K. </context> | us-gaap:CommonStockParOrStatedValuePerShare |
On August 4, 2022, Exelon entered into an agreement with certain underwriters in connection with an underwritten public offering (the “Offering”) of 11.3 million shares (the “Shares”) of its Common stock, no par value (“Common Stock”). The Shares were sold to the underwriters at a price per share of $ 43.32 . Exelon also granted the underwriters an option to purchase an additional 1.695 million shares of Common stock also at the price per share of $ 43.32 . On August 5, 2022, the underwriters exercised the option in full. The net proceeds from the Offering and the exercise of the underwriters’ option were $ 563 million before expenses paid by Exelon. Exelon used the proceeds, together with available cash balances, to repay $ 575 million in borrowings under a $ 1.15 billion term loan credit facility. See Note 16 — Debt and Credit Agreements for additional information on Exelon’s term loan within our 2022 10-K. | text | 43.32 | perShareItemType | text: <entity> 43.32 </entity> <entity type> perShareItemType </entity type> <context> On August 4, 2022, Exelon entered into an agreement with certain underwriters in connection with an underwritten public offering (the “Offering”) of 11.3 million shares (the “Shares”) of its Common stock, no par value (“Common Stock”). The Shares were sold to the underwriters at a price per share of $ 43.32 . Exelon also granted the underwriters an option to purchase an additional 1.695 million shares of Common stock also at the price per share of $ 43.32 . On August 5, 2022, the underwriters exercised the option in full. The net proceeds from the Offering and the exercise of the underwriters’ option were $ 563 million before expenses paid by Exelon. Exelon used the proceeds, together with available cash balances, to repay $ 575 million in borrowings under a $ 1.15 billion term loan credit facility. See Note 16 — Debt and Credit Agreements for additional information on Exelon’s term loan within our 2022 10-K. </context> | us-gaap:SharePrice |
On August 4, 2022, Exelon entered into an agreement with certain underwriters in connection with an underwritten public offering (the “Offering”) of 11.3 million shares (the “Shares”) of its Common stock, no par value (“Common Stock”). The Shares were sold to the underwriters at a price per share of $ 43.32 . Exelon also granted the underwriters an option to purchase an additional 1.695 million shares of Common stock also at the price per share of $ 43.32 . On August 5, 2022, the underwriters exercised the option in full. The net proceeds from the Offering and the exercise of the underwriters’ option were $ 563 million before expenses paid by Exelon. Exelon used the proceeds, together with available cash balances, to repay $ 575 million in borrowings under a $ 1.15 billion term loan credit facility. See Note 16 — Debt and Credit Agreements for additional information on Exelon’s term loan within our 2022 10-K. | text | 1.695 | sharesItemType | text: <entity> 1.695 </entity> <entity type> sharesItemType </entity type> <context> On August 4, 2022, Exelon entered into an agreement with certain underwriters in connection with an underwritten public offering (the “Offering”) of 11.3 million shares (the “Shares”) of its Common stock, no par value (“Common Stock”). The Shares were sold to the underwriters at a price per share of $ 43.32 . Exelon also granted the underwriters an option to purchase an additional 1.695 million shares of Common stock also at the price per share of $ 43.32 . On August 5, 2022, the underwriters exercised the option in full. The net proceeds from the Offering and the exercise of the underwriters’ option were $ 563 million before expenses paid by Exelon. Exelon used the proceeds, together with available cash balances, to repay $ 575 million in borrowings under a $ 1.15 billion term loan credit facility. See Note 16 — Debt and Credit Agreements for additional information on Exelon’s term loan within our 2022 10-K. </context> | us-gaap:StockIssuedDuringPeriodSharesNewIssues |
On August 4, 2022, Exelon entered into an agreement with certain underwriters in connection with an underwritten public offering (the “Offering”) of 11.3 million shares (the “Shares”) of its Common stock, no par value (“Common Stock”). The Shares were sold to the underwriters at a price per share of $ 43.32 . Exelon also granted the underwriters an option to purchase an additional 1.695 million shares of Common stock also at the price per share of $ 43.32 . On August 5, 2022, the underwriters exercised the option in full. The net proceeds from the Offering and the exercise of the underwriters’ option were $ 563 million before expenses paid by Exelon. Exelon used the proceeds, together with available cash balances, to repay $ 575 million in borrowings under a $ 1.15 billion term loan credit facility. See Note 16 — Debt and Credit Agreements for additional information on Exelon’s term loan within our 2022 10-K. | text | 563 | monetaryItemType | text: <entity> 563 </entity> <entity type> monetaryItemType </entity type> <context> On August 4, 2022, Exelon entered into an agreement with certain underwriters in connection with an underwritten public offering (the “Offering”) of 11.3 million shares (the “Shares”) of its Common stock, no par value (“Common Stock”). The Shares were sold to the underwriters at a price per share of $ 43.32 . Exelon also granted the underwriters an option to purchase an additional 1.695 million shares of Common stock also at the price per share of $ 43.32 . On August 5, 2022, the underwriters exercised the option in full. The net proceeds from the Offering and the exercise of the underwriters’ option were $ 563 million before expenses paid by Exelon. Exelon used the proceeds, together with available cash balances, to repay $ 575 million in borrowings under a $ 1.15 billion term loan credit facility. See Note 16 — Debt and Credit Agreements for additional information on Exelon’s term loan within our 2022 10-K. </context> | us-gaap:ProceedsFromIssuanceOrSaleOfEquity |
On August 4, 2022, Exelon entered into an agreement with certain underwriters in connection with an underwritten public offering (the “Offering”) of 11.3 million shares (the “Shares”) of its Common stock, no par value (“Common Stock”). The Shares were sold to the underwriters at a price per share of $ 43.32 . Exelon also granted the underwriters an option to purchase an additional 1.695 million shares of Common stock also at the price per share of $ 43.32 . On August 5, 2022, the underwriters exercised the option in full. The net proceeds from the Offering and the exercise of the underwriters’ option were $ 563 million before expenses paid by Exelon. Exelon used the proceeds, together with available cash balances, to repay $ 575 million in borrowings under a $ 1.15 billion term loan credit facility. See Note 16 — Debt and Credit Agreements for additional information on Exelon’s term loan within our 2022 10-K. | text | 575 | monetaryItemType | text: <entity> 575 </entity> <entity type> monetaryItemType </entity type> <context> On August 4, 2022, Exelon entered into an agreement with certain underwriters in connection with an underwritten public offering (the “Offering”) of 11.3 million shares (the “Shares”) of its Common stock, no par value (“Common Stock”). The Shares were sold to the underwriters at a price per share of $ 43.32 . Exelon also granted the underwriters an option to purchase an additional 1.695 million shares of Common stock also at the price per share of $ 43.32 . On August 5, 2022, the underwriters exercised the option in full. The net proceeds from the Offering and the exercise of the underwriters’ option were $ 563 million before expenses paid by Exelon. Exelon used the proceeds, together with available cash balances, to repay $ 575 million in borrowings under a $ 1.15 billion term loan credit facility. See Note 16 — Debt and Credit Agreements for additional information on Exelon’s term loan within our 2022 10-K. </context> | us-gaap:ProceedsFromRepaymentsOfDebt |
On August 4, 2022, Exelon entered into an agreement with certain underwriters in connection with an underwritten public offering (the “Offering”) of 11.3 million shares (the “Shares”) of its Common stock, no par value (“Common Stock”). The Shares were sold to the underwriters at a price per share of $ 43.32 . Exelon also granted the underwriters an option to purchase an additional 1.695 million shares of Common stock also at the price per share of $ 43.32 . On August 5, 2022, the underwriters exercised the option in full. The net proceeds from the Offering and the exercise of the underwriters’ option were $ 563 million before expenses paid by Exelon. Exelon used the proceeds, together with available cash balances, to repay $ 575 million in borrowings under a $ 1.15 billion term loan credit facility. See Note 16 — Debt and Credit Agreements for additional information on Exelon’s term loan within our 2022 10-K. | text | 1.15 | monetaryItemType | text: <entity> 1.15 </entity> <entity type> monetaryItemType </entity type> <context> On August 4, 2022, Exelon entered into an agreement with certain underwriters in connection with an underwritten public offering (the “Offering”) of 11.3 million shares (the “Shares”) of its Common stock, no par value (“Common Stock”). The Shares were sold to the underwriters at a price per share of $ 43.32 . Exelon also granted the underwriters an option to purchase an additional 1.695 million shares of Common stock also at the price per share of $ 43.32 . On August 5, 2022, the underwriters exercised the option in full. The net proceeds from the Offering and the exercise of the underwriters’ option were $ 563 million before expenses paid by Exelon. Exelon used the proceeds, together with available cash balances, to repay $ 575 million in borrowings under a $ 1.15 billion term loan credit facility. See Note 16 — Debt and Credit Agreements for additional information on Exelon’s term loan within our 2022 10-K. </context> | us-gaap:ShortTermBankLoansAndNotesPayable |
On August 4, 2022, Exelon executed an equity distribution agreement (“Equity Distribution Agreement”), with certain sales agents and forward sellers and certain forward purchasers, establishing an ATM equity distribution program under which it may offer and sell shares of its Common stock, having an aggregate gross sales price of up to $ 1.0 billion. Exelon has no obligation to offer or sell any shares of Common stock under the Equity Distribution Agreement and may, at any time, suspend or terminate offers and sales under the Equity Distribution Agreement. In the fourth quarter 2023, Exelon issued approximately 3.6 million shares of Common stock at an average gross price of $ 39.58 per share. In the third quarter 2024, Exelon issued approximately 4 million shares of Common Stock at an average gross price of $ 37.60 per share. The net proceeds from the 2023 and 2024 issuances were $ 140 million and $ 148 million, which were used for general corporate purposes. As of December 31, 2024, $ 708 million of Common stock remained available for sale pursuant to the ATM program. | text | 3.6 | sharesItemType | text: <entity> 3.6 </entity> <entity type> sharesItemType </entity type> <context> On August 4, 2022, Exelon executed an equity distribution agreement (“Equity Distribution Agreement”), with certain sales agents and forward sellers and certain forward purchasers, establishing an ATM equity distribution program under which it may offer and sell shares of its Common stock, having an aggregate gross sales price of up to $ 1.0 billion. Exelon has no obligation to offer or sell any shares of Common stock under the Equity Distribution Agreement and may, at any time, suspend or terminate offers and sales under the Equity Distribution Agreement. In the fourth quarter 2023, Exelon issued approximately 3.6 million shares of Common stock at an average gross price of $ 39.58 per share. In the third quarter 2024, Exelon issued approximately 4 million shares of Common Stock at an average gross price of $ 37.60 per share. The net proceeds from the 2023 and 2024 issuances were $ 140 million and $ 148 million, which were used for general corporate purposes. As of December 31, 2024, $ 708 million of Common stock remained available for sale pursuant to the ATM program. </context> | us-gaap:StockIssuedDuringPeriodSharesNewIssues |
On August 4, 2022, Exelon executed an equity distribution agreement (“Equity Distribution Agreement”), with certain sales agents and forward sellers and certain forward purchasers, establishing an ATM equity distribution program under which it may offer and sell shares of its Common stock, having an aggregate gross sales price of up to $ 1.0 billion. Exelon has no obligation to offer or sell any shares of Common stock under the Equity Distribution Agreement and may, at any time, suspend or terminate offers and sales under the Equity Distribution Agreement. In the fourth quarter 2023, Exelon issued approximately 3.6 million shares of Common stock at an average gross price of $ 39.58 per share. In the third quarter 2024, Exelon issued approximately 4 million shares of Common Stock at an average gross price of $ 37.60 per share. The net proceeds from the 2023 and 2024 issuances were $ 140 million and $ 148 million, which were used for general corporate purposes. As of December 31, 2024, $ 708 million of Common stock remained available for sale pursuant to the ATM program. | text | 39.58 | perShareItemType | text: <entity> 39.58 </entity> <entity type> perShareItemType </entity type> <context> On August 4, 2022, Exelon executed an equity distribution agreement (“Equity Distribution Agreement”), with certain sales agents and forward sellers and certain forward purchasers, establishing an ATM equity distribution program under which it may offer and sell shares of its Common stock, having an aggregate gross sales price of up to $ 1.0 billion. Exelon has no obligation to offer or sell any shares of Common stock under the Equity Distribution Agreement and may, at any time, suspend or terminate offers and sales under the Equity Distribution Agreement. In the fourth quarter 2023, Exelon issued approximately 3.6 million shares of Common stock at an average gross price of $ 39.58 per share. In the third quarter 2024, Exelon issued approximately 4 million shares of Common Stock at an average gross price of $ 37.60 per share. The net proceeds from the 2023 and 2024 issuances were $ 140 million and $ 148 million, which were used for general corporate purposes. As of December 31, 2024, $ 708 million of Common stock remained available for sale pursuant to the ATM program. </context> | us-gaap:SharePrice |
On August 4, 2022, Exelon executed an equity distribution agreement (“Equity Distribution Agreement”), with certain sales agents and forward sellers and certain forward purchasers, establishing an ATM equity distribution program under which it may offer and sell shares of its Common stock, having an aggregate gross sales price of up to $ 1.0 billion. Exelon has no obligation to offer or sell any shares of Common stock under the Equity Distribution Agreement and may, at any time, suspend or terminate offers and sales under the Equity Distribution Agreement. In the fourth quarter 2023, Exelon issued approximately 3.6 million shares of Common stock at an average gross price of $ 39.58 per share. In the third quarter 2024, Exelon issued approximately 4 million shares of Common Stock at an average gross price of $ 37.60 per share. The net proceeds from the 2023 and 2024 issuances were $ 140 million and $ 148 million, which were used for general corporate purposes. As of December 31, 2024, $ 708 million of Common stock remained available for sale pursuant to the ATM program. | text | 4 | sharesItemType | text: <entity> 4 </entity> <entity type> sharesItemType </entity type> <context> On August 4, 2022, Exelon executed an equity distribution agreement (“Equity Distribution Agreement”), with certain sales agents and forward sellers and certain forward purchasers, establishing an ATM equity distribution program under which it may offer and sell shares of its Common stock, having an aggregate gross sales price of up to $ 1.0 billion. Exelon has no obligation to offer or sell any shares of Common stock under the Equity Distribution Agreement and may, at any time, suspend or terminate offers and sales under the Equity Distribution Agreement. In the fourth quarter 2023, Exelon issued approximately 3.6 million shares of Common stock at an average gross price of $ 39.58 per share. In the third quarter 2024, Exelon issued approximately 4 million shares of Common Stock at an average gross price of $ 37.60 per share. The net proceeds from the 2023 and 2024 issuances were $ 140 million and $ 148 million, which were used for general corporate purposes. As of December 31, 2024, $ 708 million of Common stock remained available for sale pursuant to the ATM program. </context> | us-gaap:StockIssuedDuringPeriodSharesNewIssues |
On August 4, 2022, Exelon executed an equity distribution agreement (“Equity Distribution Agreement”), with certain sales agents and forward sellers and certain forward purchasers, establishing an ATM equity distribution program under which it may offer and sell shares of its Common stock, having an aggregate gross sales price of up to $ 1.0 billion. Exelon has no obligation to offer or sell any shares of Common stock under the Equity Distribution Agreement and may, at any time, suspend or terminate offers and sales under the Equity Distribution Agreement. In the fourth quarter 2023, Exelon issued approximately 3.6 million shares of Common stock at an average gross price of $ 39.58 per share. In the third quarter 2024, Exelon issued approximately 4 million shares of Common Stock at an average gross price of $ 37.60 per share. The net proceeds from the 2023 and 2024 issuances were $ 140 million and $ 148 million, which were used for general corporate purposes. As of December 31, 2024, $ 708 million of Common stock remained available for sale pursuant to the ATM program. | text | 37.60 | perShareItemType | text: <entity> 37.60 </entity> <entity type> perShareItemType </entity type> <context> On August 4, 2022, Exelon executed an equity distribution agreement (“Equity Distribution Agreement”), with certain sales agents and forward sellers and certain forward purchasers, establishing an ATM equity distribution program under which it may offer and sell shares of its Common stock, having an aggregate gross sales price of up to $ 1.0 billion. Exelon has no obligation to offer or sell any shares of Common stock under the Equity Distribution Agreement and may, at any time, suspend or terminate offers and sales under the Equity Distribution Agreement. In the fourth quarter 2023, Exelon issued approximately 3.6 million shares of Common stock at an average gross price of $ 39.58 per share. In the third quarter 2024, Exelon issued approximately 4 million shares of Common Stock at an average gross price of $ 37.60 per share. The net proceeds from the 2023 and 2024 issuances were $ 140 million and $ 148 million, which were used for general corporate purposes. As of December 31, 2024, $ 708 million of Common stock remained available for sale pursuant to the ATM program. </context> | us-gaap:SharePrice |
On August 4, 2022, Exelon executed an equity distribution agreement (“Equity Distribution Agreement”), with certain sales agents and forward sellers and certain forward purchasers, establishing an ATM equity distribution program under which it may offer and sell shares of its Common stock, having an aggregate gross sales price of up to $ 1.0 billion. Exelon has no obligation to offer or sell any shares of Common stock under the Equity Distribution Agreement and may, at any time, suspend or terminate offers and sales under the Equity Distribution Agreement. In the fourth quarter 2023, Exelon issued approximately 3.6 million shares of Common stock at an average gross price of $ 39.58 per share. In the third quarter 2024, Exelon issued approximately 4 million shares of Common Stock at an average gross price of $ 37.60 per share. The net proceeds from the 2023 and 2024 issuances were $ 140 million and $ 148 million, which were used for general corporate purposes. As of December 31, 2024, $ 708 million of Common stock remained available for sale pursuant to the ATM program. | text | 140 | monetaryItemType | text: <entity> 140 </entity> <entity type> monetaryItemType </entity type> <context> On August 4, 2022, Exelon executed an equity distribution agreement (“Equity Distribution Agreement”), with certain sales agents and forward sellers and certain forward purchasers, establishing an ATM equity distribution program under which it may offer and sell shares of its Common stock, having an aggregate gross sales price of up to $ 1.0 billion. Exelon has no obligation to offer or sell any shares of Common stock under the Equity Distribution Agreement and may, at any time, suspend or terminate offers and sales under the Equity Distribution Agreement. In the fourth quarter 2023, Exelon issued approximately 3.6 million shares of Common stock at an average gross price of $ 39.58 per share. In the third quarter 2024, Exelon issued approximately 4 million shares of Common Stock at an average gross price of $ 37.60 per share. The net proceeds from the 2023 and 2024 issuances were $ 140 million and $ 148 million, which were used for general corporate purposes. As of December 31, 2024, $ 708 million of Common stock remained available for sale pursuant to the ATM program. </context> | us-gaap:ProceedsFromIssuanceOfCommonStock |
On August 4, 2022, Exelon executed an equity distribution agreement (“Equity Distribution Agreement”), with certain sales agents and forward sellers and certain forward purchasers, establishing an ATM equity distribution program under which it may offer and sell shares of its Common stock, having an aggregate gross sales price of up to $ 1.0 billion. Exelon has no obligation to offer or sell any shares of Common stock under the Equity Distribution Agreement and may, at any time, suspend or terminate offers and sales under the Equity Distribution Agreement. In the fourth quarter 2023, Exelon issued approximately 3.6 million shares of Common stock at an average gross price of $ 39.58 per share. In the third quarter 2024, Exelon issued approximately 4 million shares of Common Stock at an average gross price of $ 37.60 per share. The net proceeds from the 2023 and 2024 issuances were $ 140 million and $ 148 million, which were used for general corporate purposes. As of December 31, 2024, $ 708 million of Common stock remained available for sale pursuant to the ATM program. | text | 148 | monetaryItemType | text: <entity> 148 </entity> <entity type> monetaryItemType </entity type> <context> On August 4, 2022, Exelon executed an equity distribution agreement (“Equity Distribution Agreement”), with certain sales agents and forward sellers and certain forward purchasers, establishing an ATM equity distribution program under which it may offer and sell shares of its Common stock, having an aggregate gross sales price of up to $ 1.0 billion. Exelon has no obligation to offer or sell any shares of Common stock under the Equity Distribution Agreement and may, at any time, suspend or terminate offers and sales under the Equity Distribution Agreement. In the fourth quarter 2023, Exelon issued approximately 3.6 million shares of Common stock at an average gross price of $ 39.58 per share. In the third quarter 2024, Exelon issued approximately 4 million shares of Common Stock at an average gross price of $ 37.60 per share. The net proceeds from the 2023 and 2024 issuances were $ 140 million and $ 148 million, which were used for general corporate purposes. As of December 31, 2024, $ 708 million of Common stock remained available for sale pursuant to the ATM program. </context> | us-gaap:ProceedsFromIssuanceOfCommonStock |
Exelon grants stock-based awards through its LTIP, which primarily includes performance share awards, restricted stock units, and stock options. At December 31, 2024, there were approximately 32 million shares authorized for issuance under the LTIP. For the years ended December 31, 2024, 2023, and 2022, exercised and distributed stock-based awards were primarily issued from authorized but unissued Common stock shares. | text | 32 | sharesItemType | text: <entity> 32 </entity> <entity type> sharesItemType </entity type> <context> Exelon grants stock-based awards through its LTIP, which primarily includes performance share awards, restricted stock units, and stock options. At December 31, 2024, there were approximately 32 million shares authorized for issuance under the LTIP. For the years ended December 31, 2024, 2023, and 2022, exercised and distributed stock-based awards were primarily issued from authorized but unissued Common stock shares. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized |
As of December 31, 2024, $ 8 million of total unrecognized compensation costs related to nonvested performance shares are expected to be recognized over the remaining weighted-average period of 1.7 years. | text | 8 | monetaryItemType | text: <entity> 8 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024, $ 8 million of total unrecognized compensation costs related to nonvested performance shares are expected to be recognized over the remaining weighted-average period of 1.7 years. </context> | us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions |
Exelon Corporate meets its short-term liquidity requirements primarily through the issuance of commercial paper. Exelon Corporate had $ 426 million in outstanding commercial paper borrowings as of December 31, 2024 and $ 527 million outstanding commercial paper as of December 31, 2023. | text | 426 | monetaryItemType | text: <entity> 426 </entity> <entity type> monetaryItemType </entity type> <context> Exelon Corporate meets its short-term liquidity requirements primarily through the issuance of commercial paper. Exelon Corporate had $ 426 million in outstanding commercial paper borrowings as of December 31, 2024 and $ 527 million outstanding commercial paper as of December 31, 2023. </context> | us-gaap:CommercialPaper |
Exelon Corporate meets its short-term liquidity requirements primarily through the issuance of commercial paper. Exelon Corporate had $ 426 million in outstanding commercial paper borrowings as of December 31, 2024 and $ 527 million outstanding commercial paper as of December 31, 2023. | text | 527 | monetaryItemType | text: <entity> 527 </entity> <entity type> monetaryItemType </entity type> <context> Exelon Corporate meets its short-term liquidity requirements primarily through the issuance of commercial paper. Exelon Corporate had $ 426 million in outstanding commercial paper borrowings as of December 31, 2024 and $ 527 million outstanding commercial paper as of December 31, 2023. </context> | us-gaap:CommercialPaper |
As of December 31, 2024, Exelon Corporate had a $ 900 million aggregate bank commitment under its existing syndicated revolving facility in which $ 471 million was available to support additional commercial paper as of December 31, 2024. Exelon Corporate had $ 3 million outstanding letters of credit as of December 31, 2024. See Note 16 — Debt and Credit Agreements of the Combined Notes to Consolidated Financial Statements for additional information regarding Exelon Corporate’s credit agreement. | text | 900 | monetaryItemType | text: <entity> 900 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024, Exelon Corporate had a $ 900 million aggregate bank commitment under its existing syndicated revolving facility in which $ 471 million was available to support additional commercial paper as of December 31, 2024. Exelon Corporate had $ 3 million outstanding letters of credit as of December 31, 2024. See Note 16 — Debt and Credit Agreements of the Combined Notes to Consolidated Financial Statements for additional information regarding Exelon Corporate’s credit agreement. </context> | us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity |
As of December 31, 2024, Exelon Corporate had a $ 900 million aggregate bank commitment under its existing syndicated revolving facility in which $ 471 million was available to support additional commercial paper as of December 31, 2024. Exelon Corporate had $ 3 million outstanding letters of credit as of December 31, 2024. See Note 16 — Debt and Credit Agreements of the Combined Notes to Consolidated Financial Statements for additional information regarding Exelon Corporate’s credit agreement. | text | 471 | monetaryItemType | text: <entity> 471 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024, Exelon Corporate had a $ 900 million aggregate bank commitment under its existing syndicated revolving facility in which $ 471 million was available to support additional commercial paper as of December 31, 2024. Exelon Corporate had $ 3 million outstanding letters of credit as of December 31, 2024. See Note 16 — Debt and Credit Agreements of the Combined Notes to Consolidated Financial Statements for additional information regarding Exelon Corporate’s credit agreement. </context> | us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity |
As of December 31, 2024, Exelon Corporate had a $ 900 million aggregate bank commitment under its existing syndicated revolving facility in which $ 471 million was available to support additional commercial paper as of December 31, 2024. Exelon Corporate had $ 3 million outstanding letters of credit as of December 31, 2024. See Note 16 — Debt and Credit Agreements of the Combined Notes to Consolidated Financial Statements for additional information regarding Exelon Corporate’s credit agreement. | text | 3 | monetaryItemType | text: <entity> 3 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024, Exelon Corporate had a $ 900 million aggregate bank commitment under its existing syndicated revolving facility in which $ 471 million was available to support additional commercial paper as of December 31, 2024. Exelon Corporate had $ 3 million outstanding letters of credit as of December 31, 2024. See Note 16 — Debt and Credit Agreements of the Combined Notes to Consolidated Financial Statements for additional information regarding Exelon Corporate’s credit agreement. </context> | us-gaap:LettersOfCreditOutstandingAmount |
On August 29, 2024, Exelon Corporate entered into a new revolving credit facility with an aggregate bank commitment of $ 900 million at a variable interest rate of SOFR plus 1.275 % which replaced its existing $ 900 million syndicated revolving credit facility, and extended the maturity date to August 29, 2029. | text | 900 | monetaryItemType | text: <entity> 900 </entity> <entity type> monetaryItemType </entity type> <context> On August 29, 2024, Exelon Corporate entered into a new revolving credit facility with an aggregate bank commitment of $ 900 million at a variable interest rate of SOFR plus 1.275 % which replaced its existing $ 900 million syndicated revolving credit facility, and extended the maturity date to August 29, 2029. </context> | us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity |
On August 29, 2024, Exelon Corporate entered into a new revolving credit facility with an aggregate bank commitment of $ 900 million at a variable interest rate of SOFR plus 1.275 % which replaced its existing $ 900 million syndicated revolving credit facility, and extended the maturity date to August 29, 2029. | text | 1.275 | percentItemType | text: <entity> 1.275 </entity> <entity type> percentItemType </entity type> <context> On August 29, 2024, Exelon Corporate entered into a new revolving credit facility with an aggregate bank commitment of $ 900 million at a variable interest rate of SOFR plus 1.275 % which replaced its existing $ 900 million syndicated revolving credit facility, and extended the maturity date to August 29, 2029. </context> | us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 |
Exelon Corporate had no outstanding amounts on the revolving credit facilities as of December 31, 2024. | text | no | monetaryItemType | text: <entity> no </entity> <entity type> monetaryItemType </entity type> <context> Exelon Corporate had no outstanding amounts on the revolving credit facilities as of December 31, 2024. </context> | us-gaap:LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod |
On March 23, 2017, Exelon Corporate entered into a term loan agreement for $ 500 million. The loan agreement was renewed in the first quarter of 2024 and was bifurcated into two tranches of $ 350 million and $ 150 million on March 14, 2024. The agreements will expire on March 14, 2025. Pursuant to the loan agreements, loans made thereunder bear interest at a variable rate equal to SOFR plus 1.05 % and all indebtedness thereunder is unsecured. The loan agreement is reflected in Exelon Corporate's Condensed Balance Sheets within Short-term borrowings. | text | 500 | monetaryItemType | text: <entity> 500 </entity> <entity type> monetaryItemType </entity type> <context> On March 23, 2017, Exelon Corporate entered into a term loan agreement for $ 500 million. The loan agreement was renewed in the first quarter of 2024 and was bifurcated into two tranches of $ 350 million and $ 150 million on March 14, 2024. The agreements will expire on March 14, 2025. Pursuant to the loan agreements, loans made thereunder bear interest at a variable rate equal to SOFR plus 1.05 % and all indebtedness thereunder is unsecured. The loan agreement is reflected in Exelon Corporate's Condensed Balance Sheets within Short-term borrowings. </context> | us-gaap:ShortTermBankLoansAndNotesPayable |
On March 23, 2017, Exelon Corporate entered into a term loan agreement for $ 500 million. The loan agreement was renewed in the first quarter of 2024 and was bifurcated into two tranches of $ 350 million and $ 150 million on March 14, 2024. The agreements will expire on March 14, 2025. Pursuant to the loan agreements, loans made thereunder bear interest at a variable rate equal to SOFR plus 1.05 % and all indebtedness thereunder is unsecured. The loan agreement is reflected in Exelon Corporate's Condensed Balance Sheets within Short-term borrowings. | text | 350 | monetaryItemType | text: <entity> 350 </entity> <entity type> monetaryItemType </entity type> <context> On March 23, 2017, Exelon Corporate entered into a term loan agreement for $ 500 million. The loan agreement was renewed in the first quarter of 2024 and was bifurcated into two tranches of $ 350 million and $ 150 million on March 14, 2024. The agreements will expire on March 14, 2025. Pursuant to the loan agreements, loans made thereunder bear interest at a variable rate equal to SOFR plus 1.05 % and all indebtedness thereunder is unsecured. The loan agreement is reflected in Exelon Corporate's Condensed Balance Sheets within Short-term borrowings. </context> | us-gaap:ShortTermBankLoansAndNotesPayable |
On March 23, 2017, Exelon Corporate entered into a term loan agreement for $ 500 million. The loan agreement was renewed in the first quarter of 2024 and was bifurcated into two tranches of $ 350 million and $ 150 million on March 14, 2024. The agreements will expire on March 14, 2025. Pursuant to the loan agreements, loans made thereunder bear interest at a variable rate equal to SOFR plus 1.05 % and all indebtedness thereunder is unsecured. The loan agreement is reflected in Exelon Corporate's Condensed Balance Sheets within Short-term borrowings. | text | 150 | monetaryItemType | text: <entity> 150 </entity> <entity type> monetaryItemType </entity type> <context> On March 23, 2017, Exelon Corporate entered into a term loan agreement for $ 500 million. The loan agreement was renewed in the first quarter of 2024 and was bifurcated into two tranches of $ 350 million and $ 150 million on March 14, 2024. The agreements will expire on March 14, 2025. Pursuant to the loan agreements, loans made thereunder bear interest at a variable rate equal to SOFR plus 1.05 % and all indebtedness thereunder is unsecured. The loan agreement is reflected in Exelon Corporate's Condensed Balance Sheets within Short-term borrowings. </context> | us-gaap:ShortTermBankLoansAndNotesPayable |
During the twelve months ended December 31, 2024, Exelon Corporate repurchased a portion of its Senior unsecured notes with a principal balance of $ 244 million outstanding in exchange for cash of $ 215 million. The repurchase was accounted for as a debt extinguishment and resulted in a pre-tax gain of $ 28 million, which is reflected on Exelon Corporate's Condensed Statement of Operations and Comprehensive income within Interest expense, net. | text | 244 | monetaryItemType | text: <entity> 244 </entity> <entity type> monetaryItemType </entity type> <context> During the twelve months ended December 31, 2024, Exelon Corporate repurchased a portion of its Senior unsecured notes with a principal balance of $ 244 million outstanding in exchange for cash of $ 215 million. The repurchase was accounted for as a debt extinguishment and resulted in a pre-tax gain of $ 28 million, which is reflected on Exelon Corporate's Condensed Statement of Operations and Comprehensive income within Interest expense, net. </context> | us-gaap:DebtInstrumentRepurchasedFaceAmount |
During the twelve months ended December 31, 2024, Exelon Corporate repurchased a portion of its Senior unsecured notes with a principal balance of $ 244 million outstanding in exchange for cash of $ 215 million. The repurchase was accounted for as a debt extinguishment and resulted in a pre-tax gain of $ 28 million, which is reflected on Exelon Corporate's Condensed Statement of Operations and Comprehensive income within Interest expense, net. | text | 215 | monetaryItemType | text: <entity> 215 </entity> <entity type> monetaryItemType </entity type> <context> During the twelve months ended December 31, 2024, Exelon Corporate repurchased a portion of its Senior unsecured notes with a principal balance of $ 244 million outstanding in exchange for cash of $ 215 million. The repurchase was accounted for as a debt extinguishment and resulted in a pre-tax gain of $ 28 million, which is reflected on Exelon Corporate's Condensed Statement of Operations and Comprehensive income within Interest expense, net. </context> | us-gaap:RepaymentsOfLongTermDebt |
During the twelve months ended December 31, 2024, Exelon Corporate repurchased a portion of its Senior unsecured notes with a principal balance of $ 244 million outstanding in exchange for cash of $ 215 million. The repurchase was accounted for as a debt extinguishment and resulted in a pre-tax gain of $ 28 million, which is reflected on Exelon Corporate's Condensed Statement of Operations and Comprehensive income within Interest expense, net. | text | 28 | monetaryItemType | text: <entity> 28 </entity> <entity type> monetaryItemType </entity type> <context> During the twelve months ended December 31, 2024, Exelon Corporate repurchased a portion of its Senior unsecured notes with a principal balance of $ 244 million outstanding in exchange for cash of $ 215 million. The repurchase was accounted for as a debt extinguishment and resulted in a pre-tax gain of $ 28 million, which is reflected on Exelon Corporate's Condensed Statement of Operations and Comprehensive income within Interest expense, net. </context> | us-gaap:GainsLossesOnExtinguishmentOfDebt |
Excludes the noncurrent Allowance for credit losses related to PECO’s installment plan receivables of $ 13 million, $ 6 million, and $ 7 million for the years ended December 31, 2024, 2023, and 2022, respectively. | text | 13 | monetaryItemType | text: <entity> 13 </entity> <entity type> monetaryItemType </entity type> <context> Excludes the noncurrent Allowance for credit losses related to PECO’s installment plan receivables of $ 13 million, $ 6 million, and $ 7 million for the years ended December 31, 2024, 2023, and 2022, respectively. </context> | us-gaap:ValuationAllowancesAndReservesBalance |
Excludes the noncurrent Allowance for credit losses related to PECO’s installment plan receivables of $ 13 million, $ 6 million, and $ 7 million for the years ended December 31, 2024, 2023, and 2022, respectively. | text | 6 | monetaryItemType | text: <entity> 6 </entity> <entity type> monetaryItemType </entity type> <context> Excludes the noncurrent Allowance for credit losses related to PECO’s installment plan receivables of $ 13 million, $ 6 million, and $ 7 million for the years ended December 31, 2024, 2023, and 2022, respectively. </context> | us-gaap:ValuationAllowancesAndReservesBalance |
Excludes the noncurrent Allowance for credit losses related to PECO’s installment plan receivables of $ 13 million, $ 6 million, and $ 7 million for the years ended December 31, 2024, 2023, and 2022, respectively. | text | 7 | monetaryItemType | text: <entity> 7 </entity> <entity type> monetaryItemType </entity type> <context> Excludes the noncurrent Allowance for credit losses related to PECO’s installment plan receivables of $ 13 million, $ 6 million, and $ 7 million for the years ended December 31, 2024, 2023, and 2022, respectively. </context> | us-gaap:ValuationAllowancesAndReservesBalance |
Molina Healthcare, Inc. provides managed healthcare services under the Medicaid and Medicare programs, and through the state insurance marketplaces (the “Marketplace”). Molina was founded in 1980 as a provider organization serving low-income families in Southern California and reincorporated in Delaware in 2002. We currently have four reportable segments consisting of: 1) Medicaid; 2) Medicare; 3) Marketplace; and 4) Other. Our reportable segments are consistent with how we currently manage the business and view the markets we serve. | text | four | integerItemType | text: <entity> four </entity> <entity type> integerItemType </entity type> <context> Molina Healthcare, Inc. provides managed healthcare services under the Medicaid and Medicare programs, and through the state insurance marketplaces (the “Marketplace”). Molina was founded in 1980 as a provider organization serving low-income families in Southern California and reincorporated in Delaware in 2002. We currently have four reportable segments consisting of: 1) Medicaid; 2) Medicare; 3) Marketplace; and 4) Other. Our reportable segments are consistent with how we currently manage the business and view the markets we serve. </context> | us-gaap:NumberOfReportableSegments |
Accrued interest receivable relating to our AFS and HTM securities is presented within “Prepaid expenses and other current assets” in the accompanying consolidated balance sheets, and amounted to $ 53 million and $ 35 million at December 31, 2023, and 2022, respectively. We do not measure an allowance for credit losses on accrued interest receivable. Instead, we write off accrued interest receivable that has not been collected within 90 days of the interest payment due date. We recognize such write-offs as a reversal of investment income. No accrued interest was written off during the year ended December 31, 2023 and 2022. | text | 53 | monetaryItemType | text: <entity> 53 </entity> <entity type> monetaryItemType </entity type> <context> Accrued interest receivable relating to our AFS and HTM securities is presented within “Prepaid expenses and other current assets” in the accompanying consolidated balance sheets, and amounted to $ 53 million and $ 35 million at December 31, 2023, and 2022, respectively. We do not measure an allowance for credit losses on accrued interest receivable. Instead, we write off accrued interest receivable that has not been collected within 90 days of the interest payment due date. We recognize such write-offs as a reversal of investment income. No accrued interest was written off during the year ended December 31, 2023 and 2022. </context> | us-gaap:InterestReceivable |
Accrued interest receivable relating to our AFS and HTM securities is presented within “Prepaid expenses and other current assets” in the accompanying consolidated balance sheets, and amounted to $ 53 million and $ 35 million at December 31, 2023, and 2022, respectively. We do not measure an allowance for credit losses on accrued interest receivable. Instead, we write off accrued interest receivable that has not been collected within 90 days of the interest payment due date. We recognize such write-offs as a reversal of investment income. No accrued interest was written off during the year ended December 31, 2023 and 2022. | text | 35 | monetaryItemType | text: <entity> 35 </entity> <entity type> monetaryItemType </entity type> <context> Accrued interest receivable relating to our AFS and HTM securities is presented within “Prepaid expenses and other current assets” in the accompanying consolidated balance sheets, and amounted to $ 53 million and $ 35 million at December 31, 2023, and 2022, respectively. We do not measure an allowance for credit losses on accrued interest receivable. Instead, we write off accrued interest receivable that has not been collected within 90 days of the interest payment due date. We recognize such write-offs as a reversal of investment income. No accrued interest was written off during the year ended December 31, 2023 and 2022. </context> | us-gaap:InterestReceivable |
We report reinsurance premiums as a reduction to premium revenue, while related reinsurance recoveries are reported as a reduction to medical care costs. In certain cases, we participate in state-run reinsurance programs for which no reinsurance premium is paid. Reinsurance premiums amounted to $ 11 million, $ 2 million, and $ 2 million for the years ended December 31, 2023, 2022, and 2021, respectively. Reinsurance recoveries amounted to $ 21 million, $ 35 million, and $ 33 million for the years ended December 31, 2023, 2022, and 2021, respectively. Reinsurance recoverable of $ 28 million, and $ 27 million, as of December 31, 2023, and 2022, respectively, is included in “Receivables” in the accompanying consolidated balance sheets. | text | 11 | monetaryItemType | text: <entity> 11 </entity> <entity type> monetaryItemType </entity type> <context> We report reinsurance premiums as a reduction to premium revenue, while related reinsurance recoveries are reported as a reduction to medical care costs. In certain cases, we participate in state-run reinsurance programs for which no reinsurance premium is paid. Reinsurance premiums amounted to $ 11 million, $ 2 million, and $ 2 million for the years ended December 31, 2023, 2022, and 2021, respectively. Reinsurance recoveries amounted to $ 21 million, $ 35 million, and $ 33 million for the years ended December 31, 2023, 2022, and 2021, respectively. Reinsurance recoverable of $ 28 million, and $ 27 million, as of December 31, 2023, and 2022, respectively, is included in “Receivables” in the accompanying consolidated balance sheets. </context> | us-gaap:PrepaidReinsurancePremiums |
We report reinsurance premiums as a reduction to premium revenue, while related reinsurance recoveries are reported as a reduction to medical care costs. In certain cases, we participate in state-run reinsurance programs for which no reinsurance premium is paid. Reinsurance premiums amounted to $ 11 million, $ 2 million, and $ 2 million for the years ended December 31, 2023, 2022, and 2021, respectively. Reinsurance recoveries amounted to $ 21 million, $ 35 million, and $ 33 million for the years ended December 31, 2023, 2022, and 2021, respectively. Reinsurance recoverable of $ 28 million, and $ 27 million, as of December 31, 2023, and 2022, respectively, is included in “Receivables” in the accompanying consolidated balance sheets. | text | 2 | monetaryItemType | text: <entity> 2 </entity> <entity type> monetaryItemType </entity type> <context> We report reinsurance premiums as a reduction to premium revenue, while related reinsurance recoveries are reported as a reduction to medical care costs. In certain cases, we participate in state-run reinsurance programs for which no reinsurance premium is paid. Reinsurance premiums amounted to $ 11 million, $ 2 million, and $ 2 million for the years ended December 31, 2023, 2022, and 2021, respectively. Reinsurance recoveries amounted to $ 21 million, $ 35 million, and $ 33 million for the years ended December 31, 2023, 2022, and 2021, respectively. Reinsurance recoverable of $ 28 million, and $ 27 million, as of December 31, 2023, and 2022, respectively, is included in “Receivables” in the accompanying consolidated balance sheets. </context> | us-gaap:PrepaidReinsurancePremiums |
We report reinsurance premiums as a reduction to premium revenue, while related reinsurance recoveries are reported as a reduction to medical care costs. In certain cases, we participate in state-run reinsurance programs for which no reinsurance premium is paid. Reinsurance premiums amounted to $ 11 million, $ 2 million, and $ 2 million for the years ended December 31, 2023, 2022, and 2021, respectively. Reinsurance recoveries amounted to $ 21 million, $ 35 million, and $ 33 million for the years ended December 31, 2023, 2022, and 2021, respectively. Reinsurance recoverable of $ 28 million, and $ 27 million, as of December 31, 2023, and 2022, respectively, is included in “Receivables” in the accompanying consolidated balance sheets. | text | 21 | monetaryItemType | text: <entity> 21 </entity> <entity type> monetaryItemType </entity type> <context> We report reinsurance premiums as a reduction to premium revenue, while related reinsurance recoveries are reported as a reduction to medical care costs. In certain cases, we participate in state-run reinsurance programs for which no reinsurance premium is paid. Reinsurance premiums amounted to $ 11 million, $ 2 million, and $ 2 million for the years ended December 31, 2023, 2022, and 2021, respectively. Reinsurance recoveries amounted to $ 21 million, $ 35 million, and $ 33 million for the years ended December 31, 2023, 2022, and 2021, respectively. Reinsurance recoverable of $ 28 million, and $ 27 million, as of December 31, 2023, and 2022, respectively, is included in “Receivables” in the accompanying consolidated balance sheets. </context> | us-gaap:InsuranceRecoveries |
We report reinsurance premiums as a reduction to premium revenue, while related reinsurance recoveries are reported as a reduction to medical care costs. In certain cases, we participate in state-run reinsurance programs for which no reinsurance premium is paid. Reinsurance premiums amounted to $ 11 million, $ 2 million, and $ 2 million for the years ended December 31, 2023, 2022, and 2021, respectively. Reinsurance recoveries amounted to $ 21 million, $ 35 million, and $ 33 million for the years ended December 31, 2023, 2022, and 2021, respectively. Reinsurance recoverable of $ 28 million, and $ 27 million, as of December 31, 2023, and 2022, respectively, is included in “Receivables” in the accompanying consolidated balance sheets. | text | 35 | monetaryItemType | text: <entity> 35 </entity> <entity type> monetaryItemType </entity type> <context> We report reinsurance premiums as a reduction to premium revenue, while related reinsurance recoveries are reported as a reduction to medical care costs. In certain cases, we participate in state-run reinsurance programs for which no reinsurance premium is paid. Reinsurance premiums amounted to $ 11 million, $ 2 million, and $ 2 million for the years ended December 31, 2023, 2022, and 2021, respectively. Reinsurance recoveries amounted to $ 21 million, $ 35 million, and $ 33 million for the years ended December 31, 2023, 2022, and 2021, respectively. Reinsurance recoverable of $ 28 million, and $ 27 million, as of December 31, 2023, and 2022, respectively, is included in “Receivables” in the accompanying consolidated balance sheets. </context> | us-gaap:InsuranceRecoveries |
We report reinsurance premiums as a reduction to premium revenue, while related reinsurance recoveries are reported as a reduction to medical care costs. In certain cases, we participate in state-run reinsurance programs for which no reinsurance premium is paid. Reinsurance premiums amounted to $ 11 million, $ 2 million, and $ 2 million for the years ended December 31, 2023, 2022, and 2021, respectively. Reinsurance recoveries amounted to $ 21 million, $ 35 million, and $ 33 million for the years ended December 31, 2023, 2022, and 2021, respectively. Reinsurance recoverable of $ 28 million, and $ 27 million, as of December 31, 2023, and 2022, respectively, is included in “Receivables” in the accompanying consolidated balance sheets. | text | 33 | monetaryItemType | text: <entity> 33 </entity> <entity type> monetaryItemType </entity type> <context> We report reinsurance premiums as a reduction to premium revenue, while related reinsurance recoveries are reported as a reduction to medical care costs. In certain cases, we participate in state-run reinsurance programs for which no reinsurance premium is paid. Reinsurance premiums amounted to $ 11 million, $ 2 million, and $ 2 million for the years ended December 31, 2023, 2022, and 2021, respectively. Reinsurance recoveries amounted to $ 21 million, $ 35 million, and $ 33 million for the years ended December 31, 2023, 2022, and 2021, respectively. Reinsurance recoverable of $ 28 million, and $ 27 million, as of December 31, 2023, and 2022, respectively, is included in “Receivables” in the accompanying consolidated balance sheets. </context> | us-gaap:InsuranceRecoveries |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.